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ABSTRACT OF DISSERTATION 
 
 
 
 
ROLE OF MATRIX METALLOPROTEINASE-2 IN ATHEROSCLEROSIS  
AND ABDOMINAL AORTIC ANEURYSMS IN APOLIPOPROTEIN E  
DEFICIENT MICE 
 
 
Matrix metalloproteinase-2 (MMP-2, gelatinase A, type IV collagenase) is 
a member of a family of zinc-dependent metalloendopeptidases that functions in 
the degradation of elastin, collagens, and other components of extracellular 
matrix (ECM). Both secretion and activation of MMP-2 are elevated in human 
atherosclerotic lesions and abdominal aortic aneurysms (AAA). In this 
dissertation project, we sought to test the hypothesis that MMP-2 plays a critical 
role in both atherosclerosis and AAA. We also sought to determine the detailed 
mechanism. We first examined the atherosclerosis and AngII-induced AAAs 
development in MMP-2-/- x apolipoprotein (apoE)-/- mice in vivo. It was 
surprising that MMP-2 deficiency did not reduce the incidence of AngII-induced 
AAAs or the size of atherosclerosis in apoE-/- mice. However, the cellular and 
ECM content of atherosclerotic plaques were modified in MMP-2-/- x apoE-/- 
mice as compared to MMP-2+/+ x apoE-/- control mice. To explain the apparent 
paradox between this result and the hypothesis, we investigated the 
morphological characteristics of the aortic wall of MMP-2-/- mice. We detected an
enhanced MMP-9 level in the aortic wall of MMP-2-/- x apoE-/- mice compared 
with MMP-2+/+ x apoE-/- mice. Interestingly, we also observed more branching 
of the elastin fibers in aortic wall of MMP-2-/- mice as compared with aorta of wild 
type mice. We also examined the behavior of macrophages from MMP-2-/- mice. 
Reduced adhesion, migration, and expression of integrin beta 3 were detected in 
MMP-2 deficient macrophages compared with wild type macrophages. Lastly, we 
examined whether MMP-2 deficiency in bone marrow-derived cells may influence 
AAAs and atherosclerosis using bone marrow transplantation technique. There 
was a significant reduction of both atherosclerosis development and AAAs 
formation in mice that were reconstituted MMP-2-/- bone marrow cells. In 
conclusion, the findings in this dissertation suggest that MMP-2 might play an 
important role in atherosclerosis and aneurysm through influencing inflammatory 
cell infiltration. 
KEYWORDS: matrix metalloproteinase-2, atherosclerosis, abdominal aortic 
aneurysm, integrin, macrophage 
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Chapter One 
Introduction 
 
I. Atherosclerosis 
 
Atherosclerosis 
 
Atherosclerosis is traditionally described as a condition that involves the 
deposition of lipids in the tunica intima and deep layers of large and medium-
sized arteries. These lipid deposits, along with other substances, form plaques 
which tend to diminish arterial elasticity and may result in a narrowing or 
blockage of the lumen in some arteries. However, the hardening of the arteries 
often occurs in advanced stages and is not a predominant feature of 
atherosclerosis. The plaque formation constricts the blood flow and ultimately 
deprives the blood supply to vital organs. Based on an official survey, coronary 
heart disease (CHD), the most common form of heart disease, was the leading 
cause of death (2,443,387 deaths; 241.7/population of 100,000) in the USA for 
2002.112 The same survey indicated that stroke, which is another major 
complication of atherosclerosis, was the third leading cause of death accounting 
for 162,672 deaths (56.4/population of 100,000).112 
 
Pathogenesis 
 
According to many epidemiological reports, a series of etiologic agents 
including cigarette smoking, dietary fat, sex hormones, and oxidative stress are 
associated with the initiation and progression of atherosclerosis. Genetic factors 
are also important in the development of atherosclerosis. For example, carriers of 
the polymorphism apo (apolipoprotein) E4 alleles have a greater risk of 
cardiovascular diseases than individuals with the apoE3/3 genotype. Genomic 
instability associated with loss of heterozygosity and mutations in DNA micro 
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satellites have been implicated in the initiation and extension of plaques.5 
Multiple genetically predisposed diseases or conditions are closely related to 
atherosclerosis as well, such as some dyslipidemias, diabetes mellitus, and 
hypertension. 
 
Pathological processes 
 
Although the exact biological process of atherosclerosis is not fully 
understood, three different stages of atherosclerosis have been described – the 
“fatty streak” stage, the fibrous plaque stage, and the complicated lesion stage. 
The appearance of a viscous, yellow streak running along the endothelial surface 
of the arteries is the earliest pathological stage of atherosclerosis. It is the result 
of accumulation of serum lipoproteins within the intima of the vessel wall. 
Microscopy reveals that varying proportions of lipid-laden foam cells (monocyte-
derived macrophages), T lymphocytes, and smooth muscle cells constitute these 
“streaks.” The lesions are focal, small, and non-obstructive. As the disease 
advances into the second stage, the fatty streak may progress to form a fibrous 
plaque, which is the result of progressive lipid accumulation and the migration 
and proliferation of smooth muscle cells. These smooth muscle cells are 
responsible for the deposition of extracellular matrix (ECM) components and 
formation of a fibrous cap that overlies a core of lipid-laden foam cells, 
extracellular lipid, and necrotic cellular debris. Growth of the fibrous plaque 
results in vascular remodeling, progressive luminal narrowing, blood-flow 
abnormalities, and usually compromises oxygen supply to the target organ. The 
last stage of atherosclerosis, the complicated lesion stage, is described as a 
calcified fibrous plaque containing various degrees of necrosis and ulceration, 
and is frequently associated with symptoms.  With increasing necrosis in the 
fibrous plaque, the arterial wall progressively weakens. Should the plaque 
rupture, the cholesterol and connective tissue underneath might be exposed. 
Consequently, rupture provokes strong blood clotting reactions, thus arterial 
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emboli can be formed. 
With the advancement of cardiovascular biology, the understanding of 
atherosclerosis has evolved rapidly over the past three decades. To date, 
atherosclerosis has been well characterized by endothelial dysfunction, intimal 
thickening, vascular smooth muscle cell (VSMC) proliferation, lipid deposition, 
cholesterol-laden foam cell (monocyte-derived macrophage) development, 
inflammatory cell accumulation, vascular matrix remodeling, excess generation of 
reactive oxygen species (ROS) and platelet activation and thrombosis. The 
balance of systemic and local inflammatory and anti-inflammatory cellular and 
molecular elements play a pivotal role in all phases of plaque development, 
progression, and degeneration.42,138,143,170 Therefore, the infiltration and 
accumulation of inflammatory cells, especially macrophages, are critical events in 
the development of atherosclerosis. The autopsies of patients who have died of 
acute coronary disease reveal that macrophage infiltration and accumulation 
have a consistently positive relationship with plaque rupture.55 Although the up-
take of oxidatively modified LDL (ox-LDL) by macrophages and their subsequent 
exit from the lesion might be anti-atherogenic in the early stage of 
atherosclerosis, macrophages produce a diverse array of atherogenic cytokines, 
chemoattractants, and proteolytic enzymes including matrix metalloproteinases 
(MMPs), which can degrade all macromolecular constituents of the ECM in the 
vascular wall. 
There are several hypotheses concerning the initiation of atherosclerosis. 
The first proposes a “response-to-injury” scenario where injury to endothelial and 
smooth muscle cells triggers initial events that lead to atherosclerosis. Another 
hypothesis, oxidation, focuses on the significance of the oxidative modification of 
low density lipoprotein (LDL) in subsequent atherogenic responses, such as 
inducing the synthesis of monocyte chemo-tactic protein-1 (MCP-1) which then 
induces the recruitment of inflammatory cells to lesion areas. A third proposal, 
“response-to-retention”, places emphasis on the subendothelial retention and 
accumulation of LDL and other atherogenic lipoproteins in arteries as the primary 
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factor for initiating cholesterol-induced atherosclerosis.192 Intensive studies have 
been done to understand the molecular mechanisms underlying the progression 
of atherosclerosis. Many molecular pathways in the progression of 
atherosclerosis have been defined: 1) alterations of transforming growth factor 
(TGF)-beta, TGF-beta receptors, and Smad signaling proteins (their name comes 
from the TGF-beta homologs found in C. elegans (“Sma”) and drosophila).13,140  
2) alterations in several other peptide growth factors that regulate cell cycle and 
proliferation in atherosclerosis including epidermal growth factor (EGF), fibroblast 
growth factor (FGF), platelet-derived growth factor (PDGF), insulin-like growth 
factor (IGF), granulocyte macrophage colony stimulating factor (GM-
CSF).147,149,195  3) the altered expression of cell adhesion molecules, such as 
integrins and selectins, which serve as promoters of atherosclerosis.28,71  4) the 
involvement of proteases and tissue protease inhibitors in the progression of 
atherosclerosis by contributing to luminal thrombosis.186  5) the deregulation of 
nuclear factor kappa B (NF-κB). NF-κB is a transcription factor involved in the 
regulation and expression of a diverse array of chemokines, cytokines, growth 
factors, cell adhesion molecules, and cell cycle regulatory proteins. NF-κB 
signaling also up-regulates the expression of pro-apoptotic proteins such as Bcl-
2, and down-regulates the expression of anti-apoptotic proteins such as 
Bax.9,25,34  6) the alteration of MMP activity, which is associated with the aberrant 
regulation of ECM remodeling, leading to atherosclerosis.18,67 
 
II. Abdominal aortic aneurysms 
 
Abdominal aortic aneurysms 
 
An aneurysm is defined as a localized, blood-filled, and permanent 
dilatation of a blood vessel caused by a disease or weakening of the vascular 
wall. The word aneurysm is derived from the Greek word for “widening”.  
Connective tissue diseases such as Marfan, Ehlers-Danlos’, and Stickler 
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syndrome as well as aging, and mycosis are associated with aneurysm 
formation. 
Abdominal aortic aneurysm (AAA) is a chronic, degenerative disease 
characterized by the progressive weakening and irreversible expansion of the 
abdominal aortic wall. In 1991, the Society for Vascular Surgery and the 
International Society Cardiovascular Surgery Ad Hoc Committee on Standards in 
Reporting developed a criterion for AAA, stating the infra-renal abdominal aortic 
diameter should be more than 150% of the expected normal diameter. AAAs are 
prevalent in aged populations (2-9% of people >65 years of age) with rupture 
causing approximately 15,000 unexpected deaths every year in USA.84 The 
incidence of AAA has increased dramatically in recent decades. Factors that may 
have contributed to this increase include the increasing mean age of the 
population and improvements in diagnostic evaluation. Although there is 
variability between patients in the rate of aortic dilation and the point of rupture, 
the available method of reducing associated mortality is still the detection of  
AAAs before rupture, followed by repair of the damaged aorta. 
 
Pathogenesis 
 
Although the etiology of AAAs is unknown, several population-based 
studies and relative hazard risk assessment evaluations indicate that the 
development of AAA is significantly related to multiple factors: smoking, 
advanced age, male gender, and a family history. There are conflicting reports 
concerning the association between AAA, dyslipidemia, and hypertension. 3,115,210 
Traditionally, atherosclerosis is believed to contribute to the formation of AAAs; a 
relationship that is supported by population studies. 11,79 However, these studies 
could not distinguish causal effects and associated risk factors. In addition, 
evidence indicates that atherosclerosis is not the cause of AAAs because many 
patients developed severe atherosclerotic lesions in their aortas without 
aneurysm formation.200 Regarding family history, although the frequency of AAAs 
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in first-degree relatives is much higher when compared to the unrelated 
population, a genetic basis for this disease remains unclear. 
 
 
Pathological processes 
 
Traditional concepts of AAAs emphasize the degenerative thickening and 
dilation of the aortic wall. Immunohistochemistry and molecular biology 
experiments with human aneurysmal tissue obtained during surgery have 
consistently demonstrated large numbers of inflammatory cells in the aortic wall, 
increased cytokine and protease activity, and elevated levels of cellular 
production pro-apoptosis genes (such as p53 and p21) in vascular smooth 
muscle cells (VSMCs).76,148,201 MMPs and fibrinolytic enzymes are found to be 
more active in aneurysmal tissues than in occlusive atherosclerotic tissues. The 
upregulation of these proteases is believed to be responsible for the destruction 
of the elastin and collagen structural matrix.21,63 Moreover, the physiological 
inhibitors of these proteases, such as TIMP-2 and PAI-1, have decreased 
expression in AAA tissue. When factors such as accumulated inflammatory cells, 
vascular matrix turnover by highly activated proteolytic enzymes and depletion of 
VSMCs are present, their combined actions weaken the structural matrix of the 
abdominal aortic wall, leading to aneurysmal dilation under the high transmural 
pulse of the aorta. Consequently, these changes are accompanied by thrombus 
formation in many cases. 
Many studies suggest that the hallmark pathology of AAAs is the 
progressive and irreversible degeneration of the medial elastic lamellae. This 
destruction of elastic lamellae is considered to contribute to the aneurysmal 
dilation and enlargement. However, the vessel wall remodeling occurs by 
mechanisms that are different from any of the risk conditions mentioned 
previously.8 
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III. Matrix metalloproteinase-2 (MMP-2) 
 
General information regarding MMPs 
 
The matrix metalloproteinase (MMP) family is composed of over 30 
endopeptideases in which at least 17 are human MMPs.  These enzymes share 
some common features: they have the ability to cleave various macromolecules 
of the ECM; they are comprised of the calcium and zinc ions necessary for 
catalytic activity; they are produced and secreted as latent forms, except for 
MMP-11, 27 and MT-MMPs; and they are inhibited by their endogenous 
inhibitors, i.e., tissue inhibitor of matrix metalloproteinases (TIMPs). MMPs are 
classified into 6 subgroups based on their substrate specificity and internal 
homologies (Figure 1.1): collagenases (MMP-1, -8, -13, -18), gelatinases (MMP-
2, -9), stromelysins (MMP-3, -10, -11, -19), matrilysins (MMP-7, -26), membrane-
type MMPs (MT-MMPs: MMP-14, -15, -16, -17, -24, -25), and non-classified 
MMPs (MMP-12, -20, -21, -22, -23, -27, -28). They are involved in extracellular 
matrix degradation in many physiological and pathological processes such as 
wound healing, ovulation, cancer metastasis, and inflammatory joint 
diseases.70,190,206 They may be implicated in cardiovascular diseases such as 
atherosclerosis and AAAs as well. At least 14 MMPs have been characterized in 
vascular cells.147 The gelatinases (i.e. MMP-2 and MMP-9) have attracted 
attention for their elastolytic capabilities and increased levels in lesions of 
vascular diseases. 
Many MMPs are highly expressed in AAAs and atherosclerotic lesions. It 
is believed that MMPs are involved in the destruction of the ECM and are harmful 
in vascular diseases such as AAAs and atherosclerosis. However, more 
evidence suggests that the role of MMPs is not limited in turnover of the ECM 
components. Actually, they have multiple substrates that are involved in the 
control of cellular behavior. Therefore, new evaluations of these enzymes should 
be performed to elucidate the underlying mechanisms in more detail. There are 
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several studies demonstrating direct genetic evidence of the role of MMPs and 
their inhibitors in vascular diseases. A few relevant conclusions are: MMP-1 
transgenic mice on an apoE-/- background demonstrated decreased 
atherosclerotic lesions. This suggests that the remodeling of the neointimal ECM 
by MMP-1 is beneficial in atherosclerosis;117 MMP-2 deficiency reduced intimal 
hyperplasia in a mouse carotid artery blood flow cessation model;101,114 MMP-3 
inactivation increased the size of atherosclerotic lesions and decreased the 
formation of aneurysm in apoE null mice;183 MMP-9 deficiency but not MMP-12 
deficiency reduced AAA formation induced by elastase perfusion in mice;162 
deficiency of MMP-9, MMP-2, and MMP-12 reduced AAA formation induced by 
abluminal application of calcium chloride in mice;126,125 MMP-9 deficiency, but not 
MMP-12 deficiency, protected against atherosclerotic plaque growth; both 
deficiency of MMP-9 and 12 protected against atherosclerotic media destruction 
and ectasia in apoE null mice;129 TIMP (tissue inhibitor of MMPs)-1 inactivation 
prevents development of atherosclerosis, but enhances aneurysm formation 182 
in apoE null mice; Lemaitre et al. reported that TIMP-1 deficiency caused an 
increased medial degradation with pseudo-aneurysm formation in apoE-/- 
mice.118 
 
MMP-2 
 
The structure of the MMP-2 protein: MMP proteins have high sequence 
homology. Almost all of the MMP proteins contain the following domains:  a 
signal sequence; a pro-peptide domain with a strictly conserved cystine residue 
which contains a Zn-ligating thiol (SH) group; a catalytic domain with a Zn 
binding site and a hemopexin-like C’ terminal domain which contains four repeats 
(Figure 1.2). The only exception are the matrilysins, the smallest members of 
MMPs family, which do not have the hemopexin-like domain.78 Gelatinases 
(MMP-2 and 9) have 3 contiguous fibronectin type II-like domains, which may 
contribute to specificity in substrate binding of these enzymes.144 MMP-2, a 72 
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kDa protein, is called a gelatinase A or type IV collagenase because of its 
substrates. 
MMP-2 gene expression: Unlike other MMPs, MMP-2 is primarily 
expressed by many cells, including VSMCs,63 macrophages,180, 213 fibroblasts, 154 
endothelial cells,91 myocytes,33 mast cells,56 and lymphocytes.54 The promoter 
region of MMP-2 is unique because of the absence of the TATA and CAAT box.89 
It also lacks an upstream transforming growth factor (TGF) beta inhibitory 
element (TIE).135 This suggests that MMP-2 is essentially a "housekeeping" 
gene. Therefore, the transcription of MMP-2 gene is rarely suppressed. For 
example, TGF-beta, a regulator of many MMPs, actually upregulates MMP-2 
mRNA levels and increases the half-life of MMP-2 mRNA in human fibroblasts.154 
Many other cytokines can upregulate MMP-2 gene expression, especially under 
pathological conditions such as inflammation. For instance, granulocyte-
macrophage colony-stimulating factor (GM-CSF) upregulates MMP-2 expression 
at both the transcription 202 and translation levels 194 in head and neck cancer 
cells. Interleukin (IL)-12 and IL-18 enhance MMP-2 mRNA levels separately and 
synergistically in monocytic cells.1 Also, Eichler et al. and Kim et al. showed TGF-
alpha enhanced MMP-2 expression in mouse blastocysts and human retinal 
pigment epithelial cells,50,108  while Cipollone et al. showed that macrophage and 
smooth muscle cell PGE2 increases the production of MMP-2 in the vascular 
wall.32 
The activation of MMP-2: As with other members of the MMP family, 
MMP-2 is synthesized as a latent zymogen.  MMP-2 does not undergo 
spontaneous activation.110 The pro-domain is critical for keeping MMP-2 in the 
inactive state. The thiol group of the conserved cystine of the pro-domain binds 
to the catalytic zinc atom in the active site of the catalytic domain, thus keeping 
the enzyme inactive. The proteolytic removal of the pro-domain at Asn37-Leu38 
is essential for the activation of MMP-2. After the removal of the pro-domain by 
chemicals or other proteases, the catalytic cleft is exposed to water to hydrolyze 
and disrupt the interaction of the thiol group (SH) of the conserved cysteine 
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residue in the pro-domain to the Zn atom.191 Under physiological conditions, 
proMMP-2 is fundamentally expressed, but stable at low concentrations through 
the control of activation or inhibition by TIMP-2. 
MMP-2 has a unique cell surface mode of activation in which it forms a 
ternary complex with MMP-14 (MT1-MMP) and TIMP-2. The N-terminal of TIMP-
2, which has the inhibitory ability, binds to the catalytic domain of MMP-14, and 
the C'-terminal of TIMP-2 binds to the hemopexin-like domain of proMMP-2. 
Since MMP-14 anchors to the plasma membrane through the transmembrane 
domain and leaves the catalytic domain exposed extracellularly, the formation of 
this ternary complex allows proMMP-2 to localize at the cell surface. Once 
formed, it is cleaved and activated by a TIMP-free active MMP-14 molecule that 
localizes nearby 100. Therefore, TIMP-2 is required for MMP-2 activation at low 
concentrations (Figure 1.3). As mentioned above, at high concentrations, TIMP-2 
binds to a binding site of activated MMP-2 and reduces the activity of MMP-2. 
TIMP-2 also inhibits the activation of proMMP-2 by blocking all active MMP-14. 
Additional, several integrins, including alpha 2 beta 1 and alpha v beta 3, 
facilitate this process via anchoring the hemopexin domain of proMMP-2 on the 
cell surface.184 It was reported that MMP-14 may activate alpha v beta 3 integrin 
through proteolytic cleavage.45 
Following the initial removal of the pro-peptide to give a 64-kDa 
intermediate, the final processing to the fully active form of 62-kDa MMP-2 
requires a further proteolytic cleavage at Asn80-Phe81 by another fully activated 
MMP-2 molecule.193 Integrin alpha v beta 3 may promote this by providing a 
platform for autocatalytic interaction between the two MMP-2 molecules.46 
Mature MMP-2 can either bind to another cell surface anchor protein or be 
released. Besides the major activation pathway as described above, there are 
several other pathways that contribute to the activation of MMP-2. It was reported 
that proMMP-2 could be activated by physiological concentrations of uPA-
plasmin through a mechanism independent of the action of other metallo-or acid 
proteinases.139 Two coagulation factors, thrombin and factor Xa, have been 
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demonstrated to activate proMMP-2 in cultured VSMCs.66,165 Rajagopalan et al. 
reported the activity of pro-MMP-2 is upregulated by ROS produced by 
macrophage-derived foam cells.164 There is evidence that NF-κB, a critical 
inflammatory factor, induces the activation of MMP-2.158,159 In addition, 
osteopontin deficiency led to a decreased activity of both MMP-2 and MMP-9,20 
and AngII-induced MMP-2 release from endothelial cells is mediated by TNF-
alpha.7 More recently, it was reported that in macrophages, oxidized LDLs (ox-
LDLs) markedly elevated the levels of MMP-14 mRNA and protein.166 However, 
the cross-talk between cell signaling pathways in MMP-2 activation is poorly 
understood. 
 The inhibition, catabolism, and clearance of MMP-2: The synthesis of 
MMP-2 is hardly suppressed at the transcription and post-transcription levels. 
Since MMP-2 is synthesized as a zymogen, the regulation of MMP-2 is mainly 
through regulation of the activity and/or activation of the enzyme. It should be 
kept in mind that proMMP-2 is stable under physiological conditions, i.e. the 
zymogen is not activated spontaneously. Mature MMP-2 molecules released 
from the cell surface may either maintain their active state or be inhibited by 
binding to TIMP-2, which is the endogenous inhibitor of MMP-2. The MMP-
2/TIMP-2 complex retains 10% of proteolytic activity of MMP-2. In addition, at 
high levels, TIMP-2 regulates the activation of pro-MMP-2 by blocking all active 
MT1-MMP.92 The fibronectin type II domain of MMP-2 interacts with 
thrombospondin properdin-like repeat (TSR) domain of thrombospondins (TSPs) 
to form a complex.217 Endocytosis of  the MMP-2/ TSP-2 complex,  mediated by 
low density lipoprotein-related receptor protein (LRP) scavenger receptor, is 
another mechanism of MMP-2 control.218 The LRP mediated endocytosis is 
regulated by a 39 kDa LRP-associated protein (RAP), which binds and 
antagonizes the function of LRP and other members of the LDL receptor family. 
LRP also mediates the clearance of the proMMP-2/TIMP-2 complex through a 
TSP independent pathway.51 More recently, it was reported that furin, which is a 
serine protease, directly cleaves proMMP-2 within the trans-Golgi network (TGN) 
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to create an inactive form MMP-2 (63 kDa). This 63 kDa inactive MMP-2 cannot 
be further cleaved to an active form.22 
 
Substrates of MMP-2 
 
 ECM components: The three-dimensional organization of the ECM 
molecules, including elastin, collagen, proteoglycans and structural 
glycoproteins, is optimal for the function of vessel walls. ECM components can 
be degraded and removed by proteolytic enzymes (especially MMPs) and cell 
(such as macrophages and fibroblasts) phagocytosis. MMP-2 has various ECM 
substrates including native collagen types (I, IV, V, VII, X, XI), denatured 
collagens (gelatin), elastin, fibronectin, laminin-5, aggrecan, brevican, neurocan, 
decorin, and vitronectin. Among these ECM molecules, fibronectin, vitronectin, 
and laminin are structural glycoproteins that have a multi-domain structure and 
enable interactions between cells and ECM constituents.29 Collagen and elastin 
are the major protein components of vascular wall. The three repeats of 
fibronectin type II inserts in the catalytic domain of MMP-2 are required to bind 
and cleave collagen and elastin. 144 
 Regulators of cell behavior: The ECM not only provides a structural 
framework to support cell adhesion and tissue integrity, but it also controls cell 
behavior by influencing signaling molecules. The ECM serves as a reservoir for 
many cytokines and chemokines that may affect cell adhesion and migration to 
their destined sites. When the ECM is degraded, these molecules are released. 
For example, TGF-beta can be released after degradation of the collagen-
associated proteoglycan decorin, which is an anchor protein of TGF-beta.95 
Several MMPs (including MMP-2) may release TGF-beta through this pathway. 
MMP-2 and MMP-9 may proteolytically cleave and activate latent TGF-beta.219 
Moreover, MMP-2 may modulate the activity of fibroblast growth factor (FGF) by 
cleavage of the FGF receptor-1.119 MMP-2, by binding to IGF and inhibiting its 
activity, may degrade insulin-like growth factor binding protein (IGFBP), which 
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may enhance the activity of IGF. In addition, MMP-2 is involved in the activation 
of endothelin-1 (ET-1). MMP-2 may cleave the Gly32-Leu33 bond of latent ET-1 
(1-38) forming the potent vasoconstrictor ET-1 (1-32). This may increase cell 
adhesion ability through regulating endothelial expression of adhesion molecules 
such as E-selectin and intracellular adhesion molecule (ICAM).58 Furthermore, 
active ET-1 produced by MMP-2 upregulates CD11b/CD18 expression on human 
neutrophils.59 It was reported that MMP-2 was involved in the shedding of 
vascular cell adhesion molecule (VCAM-1) directly as well.91 
 Involvement in the expression and activation of other MMPs: It is 
known that the active form of MMP-2 can activate proMMP-9 on the surface of 
cancer cells. 65 On the contrary, Esparza et al. reported that the MT1-MMP/TIMP-
2/MMP-2 complex, while facilitating activation of proMMP-2, could be involved in 
the regulation of MMP-9 expression.53 Although these findings suggest MMP-2 
may play several roles in the regulation of MMP-9 activity, the factors controlling 
these effects are largely unknown. MMP-2 also facilitates MMP-14 processing 
and activating the zymogen form of MMP-13.111 
 
IV. Potential mechanisms of MMP-2 involvement in the 
development of atherosclerosis 
 
 Both secreted and active MMP-2 are elevated in human atherosclerotic 
lesions.141,156 Due to lack of a selective MMP-2 inhibitor, MMP-2 deficient mice 
have been created to determine the role of MMP-2 in atherosclerosis. As 
mentioned above, MMP-2 deficient mice have reduced intimal hyperplasia in 
mouse carotid artery blood flow cessation model. 101,114 
 
MMP-2 is involved in the remodeling of the vascular wall 
 
 The ECM of the vascular wall is a complex network is comprised of many 
high molecular weight proteins and polysaccharides. These molecules are 
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organized according to which cells secreted them. The surrounding cells are also 
involved in the organization of ECM molecules. The three-dimensional structure 
of the ECM provides a support for cell adhesion, facilitating tissue integrity of 
vascular walls. Furthermore, the ECM may modulate signaling pathways that 
control numerous cellular behaviors including growth, differentiation, survival and 
morphogenesis.128 The ECM also serves as a reservoir for growth factors and a 
binding site of lipoprotein, which contributes to the accumulation and oxidation of 
LDL particles in the arterial wall. Turnover of ECM plays a key role in 
cardiovascular diseases, including atherosclerosis and AAAs.122 As mentioned 
previously, MMP-2 has various substrates of ECM components. Among these 
ECM molecules, collagen and elastin are the major protein components of the 
vascular wall. In particular, type I collagen is the major (60%) fibrillar collagen 
detectable in blood vessels.137 Elastin is the most abundant protein in the large 
arteries, and strengthens the aortic wall against pulse waves. The disruption of 
elastin not only leads to dissection of arteries, but also contributes to proliferation 
of VSMCs and obstructive arterial diseases.120 Other molecules involved are 
fibronectin, vitronectin and laminin, and structural glycoproteins which have a 
multi-domain structure and enable interactions between cells and ECM 
constituents.29 
 
MMP-2 is involved in inflammatory cell adhesion and migration 
 
 Inflammatory cell recruitment and invasion are critical for the initiation and 
progression of atherosclerosis. Although macrophage accumulation is especially 
important for ox-LDL clearance, accumulation of lipid-laden foam cells results in 
increased size of atherosclerosis, cell death and necrotic core formation. MMP-2 
facilitates cell migration in pathological processes.69,114 In mice, MMP-2 
deficiency has been shown to suppress VSMC migration from the media to the 
intima of the vessel wall.101,114 Some studies suggest MMP-2 might influence 
neutrophil-endothelial adhesion by cleaving the latent endothelin-1 (ET-1), 
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creating the potent ET-1 and upregulating CD11b/CD18 expression.58,59 Since 
the recruitment of macrophages is one of the initial steps of atherosclerosis 
development, MMP-2 might play an important role in the early stages of 
atherosclerosis. 
 
MMP-2 is involved in platelet aggregation 
 
 Intravascular thrombosis is one of the most crucial pathological events in 
various cardiovascular diseases. Thrombosis deteriorates the hardening and 
narrowing of blood vessels as well as turbulent blood flow formation and 
therefore exacerbates vascular diseases. An injury to the surface of a blood 
vessel attracts platelet aggregation and leads to primary thrombus formation. 
Von Willebrand factor (vWF), a long-chain macromolecule, induces the activation 
of platelet glycoproteins (GPs) such as GPIb and GPIIb/IIIa (fibrinogen receptor). 
These glycoproteins mediate the mechano-chemical interactions between 
platelet-platelet and platelet-vascular wall and consequently lead to platelet 
adhesion and aggregation. During platelet aggregation, MMP-2 is translocated 
from the cytosol to the platelet surface and is released.174 Solid phase vWF 
induces the release of MMP-2 from platelets. Human recombinant MMP-2 
potentiated the effects of vWF on platelet adhesion via upregulating GPIb. An 
inhibition of MMP-2 reduced platelet adhesion when stimulated with svWF also 
suggests the important role of MMP-2 in platelet aggregation.163 Thus, MMP-2 
might be involved in atherosclerosis progression via influencing platelet 
aggregation and thrombus formation. 
 
MMP-2 is involved in growth factor activity 
 
 The potential roles of growth factors in cardiovascular pathophysiology 
have raised considerable interest. For instance, it was reported that 
transplantation of bone marrow-derived cells containing T cells with dominant-
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negative TGF-beta receptors led to a reduced size of atherosclerotic lesions but 
increased vulnerability to rupture in LDLr-/- mice.73 MMP-2 is known to 
proteolytically cleave and activate TGF-beta.95 MMP-2 might cleave decorin, 
which is an anchor protein of TGF-beta, thus releasing TGF-beta. 219 MMP-2 also 
increases the availability of insulin-like growth factor (IGF) by degrading the IGF 
binding proteins.62 Furthermore, MMP-2 cleaves cell surface fibroblast growth 
factor (FGF) receptor-1 and releases the soluble FGF receptor into circulation. 
This soluble FGF receptor fragment is able to bind to FGF and might indirectly 
influence FGF availability. It is not known whether the removal of FGF receptors 
could influence cell response to FGF directly. 
 
MMP-2 is involved in the activity of other MMPs 
 
 Other members of the MMP family are also involved in vascular diseases. 
At least 14 MMPs have been found in vascular cells. MMP-2 is involved in the 
activation of MMP-9,65 which is another gelatinase in the MMP family and critical 
for atherosclerosis and AAA formation in some animal models. MMP-2 also 
facilitates MT-MMP to activate the zymogen form of MMP-13. There is evidence 
that MMP-13 affects the development of atherosclerosis as well.127,99,161 
 
MMP-2 influences LDL modification and VSMC contraction 
 
 More recently, it was reported that MMP-2 was involved in the modification 
of LDL in arterial walls.203 Furthermore, MMP-2 promotes aortic dilation by 
inhibiting the Ca2+ entry pathway of vascular smooth muscle contraction.27 
 
V. Potential mechanisms of MMP-2 involvement in the 
development of AAAs 
 
 Both secretion and activation of MMP-2 are augmented in human 
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AAAs.74,141 MMP-2 deficient mice have been used to determine the role of MMP-
2 in AAAs. As mentioned above, abluminal application of CaCl2-induced AAA 
formation was ablated in MMP-2 deficient mice. 
 
MMP-2 is an elastiolytic enzyme 
 
 The hallmark pathology of AAAs is the progressive and irreversible 
degeneration of the medial elastin lamellae. This destruction of elastin may 
contribute to aneurysmal dilation and enlargement. Turnover of ECM plays a key 
role in AAAs.8,122 As a major elastinase, MMP-2 is thought to be implicated in 
AAA formation. 
 
MMP-2 is involved in inflammatory cell adhesion and migration 
 
 Inflammatory cell recruitment and invasion are critical for the initiation and 
progress of AAAs. A previous study by our lab, in hyperlipidemic mice, 
demonstrated that the accumulation of macrophages in the media of aortic wall 
after AngII-infusion is the earliest pathological event in AAA formation.172 
Similarly, a clinical trial study demonstrated that the concentration of MMP-2 was 
higher for small aneurysms as compared with large aneurysms, which suggests 
that MMP-2 might contribute to early aneurysmal dilation.63 The potential role of 
MMP-2 in the early stages of AAAs might encourage the development of new 
approaches in the prevention of this disease. 
 
Other potential roles MMP-2 might play in AAAs 
 
 MMP-2 may influence the apoptosis of vascular smooth muscle cells. The 
apoptosis of VSMCs is a prominent feature of AAAs. A modification in the activity 
of growth factors by MMP-2 might influence VSMC proliferation and apoptosis. 
Intravascular thrombosis is one of the major pathological events of AAA. As 
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described above, MMP-2 potentiates the vWF effects on platelet adhesion 
through up-regulating GPIb. 163 Therefore, MMP-2 might be involved in AAA 
progression via influencing platelet aggregation and thrombus formation. 
Other members of MMP family are also involved in AAAs. As mentioned 
previously, MMP-2 is involved in the activation of MMP-9,65 which is another 
member of the gelatinase sub-family and is critical for AAA formation in a couple 
of mouse models. 
 
 The primary hypothesis of this research is that MMP-2 plays an important 
role in the formation and progression of atherosclerosis and AAA in vitro and in 
vivo. This hypothesis was tested in four specific aims: (1) to determine whether 
MMP-2 deficiency is protective for atherosclerosis and angiotensin II-induced 
AAAs in apoE-/- mice; (2) to investigate the phenotypic change in aortas of MMP-
2 deficient mice; (3) to investigate cell behavior of macrophages of MMP-2 
deficient mice; (4) to determine whether bone marrow-derived MMP-2 is critical in 
atherosclerosis and AAA formation in vivo.  The data will be presented over four 
chapters (Chapters 2-5) in this thesis. 
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Figure 1.1 Classification of proteolytic enzymes 
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Figure 1.2 Domain composition of MMP-2. Pre - signal peptide which is 
removed after it directs synthesis to the endoplasmic reticulum; Pro – a pro-
peptide with a zinc-binding SH group, which maintains enzyme latency until it is 
removed or disrupted; II - Fibronectin type II repeats, which are cysteine-rich and 
unique in MMP-2 and MMP-9; H - Hinge region; Zn - the catalytic domain 
contains the conserved zinc-binding region. 
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Figure 1.3  Activation of MMP-2 on the cell membrane MMP-2 has a unique 
cell surface mode of activation in which it forms a ternary complex with MT1-
MMP (MMP-14) and TIMP-2. The N’ terminal of TIMP-2 binds the catalytic 
domain of MT1-MMP, and the C’-terminal of TIMP-2 binds the hemopexin-like 
domain of pro-MMP-2.  The formations of this ternary complex makes pro-MMP-
2 localize at the cell surface and can be cleaved and activated by a TIMP-free 
active MT1-MMP molecule, which localizes nearby. Therefore, TIMP-2, well 
known as an endogenous inhibitor of MMP-2, is required for MMP-2 activation at 
low concentrations. At high concentrations, TIMP-2 binds to N’-terminal of 
activated MMP-2 and reduces the activity of the enzyme. Additionally, integrin 
"v$3 is another molecule that may anchor proMMP-2 on the cell surface and 
favor MMP-2 maturation. It was reported that MT1-MMP might activate "v$3 
integrin through proteolytic cleavage. 
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Chapter Two 
The Effects of MMP-2 Deficiency on Atherosclerosis and AngII-
Induced AAAs in Apolipoprotein E Deficient Mice 
 
I. Background 
 
Apolipoprotein E deficient mouse model of atherosclerosis 
 
 Atherosclerosis, a progressive disease, might be the most important 
contributor to human mortality. Most studies of atherosclerosis in humans are 
performed after the disease is highly developed, when clinical signs or symptoms 
appear. In contrast, animal models permit investigators the opportunity to study 
the initiation and progression of preclinical stages of this disease. In order to 
provide essential information for treatment and prevention of the human disease, 
animal models should closely mimic the histopathologic changes in human 
disease as well as the interaction between pathogenetic factors and the disease 
process. In past experiments involving atherosclerosis, rabbits were the preferred 
model followed by non-human primates and swine. There are monetary 
disadvantages associated with the acquirement and maintenance of these 
animals, but more importantly, the scientific community is experiencing a moral 
shift away from the use of higher mammals as research models. The advent of 
the apoE deficient mouse model (referred to in this paper as apoE-/- or apoE 
knockout), created by a targeted inactivation of the apoE gene, provides a 
desirable research subject that is relatively cost effective for both experimental 
and breeding purposes.160 Another hyperlipidemic model, LDL receptor deficient 
(LDLr-/-) mice, can have modest increased plasma total cholesterol levels, and 
require high fat diet to develop atherosclerosis. Because the pathology of 
atherosclerosis in these mice is not as well characterized as apoE-/- mice, LDLr-
/- mice were not used in this dissertation project. 
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 ApoE is a 34kD glycoprotein important for lipid metabolism. It is a 
component of all lipoprotein particles except low density lipoprotein (LDL). ApoE 
is a high affinity ligand of the LDL receptor, and the chylomicron-remnant 
receptor (LRP) on liver cells. Therefore, apoE is essential for the specific 
uptaking of apoE-containing particles by the liver.221 ApoE also plays a key role 
in stimulating macrophage cholesterol efflux.111 Although apoE -/- mice have 
normal body weights and maturation, they tend to develop hyperlipidemia and 
atherosclerosis spontaneously. To date, the apoE-/- mouse model is considered 
to be one of the most common models in the analysis of atherosclerosis. The 
atherosclerotic plaques of apoE-/- mice are extensive, reproducible and 
demonstrate a close similarity to human atherosclerotic lesions. For instance, 
lesions in both apoE-/- mice and humans have a tendency to progress from the 
fatty streak stage to the fibrous plaque stage with obvious fibrous caps and 
necrotic lipid cores. In addition to their histological similarities to humans, apoE-/- 
mice also exhibit an exacerbation in atherosclerosis response to environmental 
pathogenetic factors, such as smoking or a “western-type” diet, which contains 
21% fat, 0.15% cholesterol, and no cholic acid.145, 185 However, it should be kept 
in mind that apoE-/- mice have several features dissimilar to humans: lesions in 
the aortic root of apoE-/- mice are foam cell-rich, rather than smooth muscle cell-
rich;  plaque rupture is not observed in these mice whereas it occurs commonly 
and leads to heart attacks in humans; and most cholesterol is carried in VLDL, 
rather than in LDL as in humans.98,130  Despite some differences, the 
atherosclerotic lesions formed in apoE-/- mice are remarkably similar to those 
found in human disease. Therefore, of all available animal models, the apoE 
deficient mouse has become widely used and accepted for research to identify 
the role of cytokines, chemoattractants and intercellular adhesion molecules in 
atherosclerosis. 
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Mouse model of AngII-induced AAAs 
 
 There are several mouse-models of chemical-induced AAAs. One such 
model uses the infusion of elastase into the infrarenal segments of mouse 
aortas.162 A second model relies on periaortic administration of calcium chloride 
between the renal branches and the iliac bifurcation.126 A more widely accepted 
model applies chronic infusion of AngII to induce reproducible AAA formation and 
accelerate atherosclerosis development in hyperlipidemic mice, including apoE-/- 
and LDLr-/- mice. The AngII infused mouse model mimics several similar 
features of AAAs in humans, such as a gender bias, luminal dilation, 
inflammatory cell recruitment, elastin fiber degeneration, and thrombi formation in 
AAA lesions. 126 There are two potential mechanisms by which AngII may induce 
AAAs. First, AngII-infusion might stimulate inflammatory cell infiltration via 
activating the NF-ĸB cascade and subsequently elevating certain cytokine levels, 
such as MCP-1 and VCAM-1. Second, AngII-infusion might enhance the activity 
of ECM degrading enzymes such as MMPs.130 Also, a previous study 
demonstrated that the initial event in AngII-induced AAAs was the accumulation 
of macrophages in the media of the suprarenal aorta. This event has been 
associated with breaks in the elastin laminae, leading to thrombus formation and 
atherosclerosis in apoE-/- mice.172 
 
The role of AngII in cardiovascular diseases 
 
 The renin-angiotensin-aldosterone system (RAAS) is one of the most 
critical in the regulation of hemodynamic homeostasis. When blood flow and 
pressure are reduced in the renal artery, renin is secreted by the juxtaglomerular 
apparatus (comprised of modified vascular smooth muscle of the afferent 
arteriole) and released into the blood. Renin is a protease which cleaves the 
inactive angiotensin I (AngI, 10 amino acid polypeptide) from a plasma protein 
(angiotensinogen). As AngI passes through the capillaries of the lungs and other 
organs, it is cleaved into AngII (an octapeptide) by angiotensin-converting 
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enzyme (ACE). Furthermore, AngII, which is the most biologically active 
component of the RAAS, is cleaved into fragments by aminopeptidases.  These 
fragments of AngII include AngIII (2-8), AngIV (3-8) and some inactive fragments 
(4-8, 5-8, and so on).131 In response to AngII and AngIII, the adrenal cortex 
synthesizes and releases aldosterone, which increases sodium and water 
retention by the collecting ducts, therefore, increasing blood volume and the 
blood pressure. In addition, AngII, directly and indirectly, enhances tubular 
reabsorption of sodium in proximal tubules as a consequence of 
glomerulotubular balance. AngII is a direct and potent vasoconstrictor of vascular 
smooth muscle by activating Ca2+ channels and releasing Ca2+ from the 
sarcoplasmic reticulum (SR). 151 Numerous clinical and laboratory data suggest 
that the RAAS is involved in the pathogenesis of atherosclerosis. The 
development of atherosclerosis in apoE-/- mice can be accelerated on a high fat 
diet or by infusion of AngII.37 Multiple receptor subtypes exist for AngII including 
AT1a, AT1b, and AT2. It is generally assumed that AngII transduces most of its 
functions through AT1a receptors.146,38 
 AngII is not only implicated in hypertension, but also as a potent pro-
inflammatory agent. In VSMCs, AngII is a potent stimulus for the generation of 
ROS.77, 211 In addition, AngII upregulates the expression of many cytokines 
(including IL-1, IL-6, IL-8, MCP-1, TNF-alpha) and growth factors (including IGF, 
TGF-beta, PDGF, bFGF) that have been implicated in the pathogenesis of 
atherosclerosis. Furthermore, AngII induces production of adhesion molecules 
(including osteopontin, VCAM-1, ICAM-1 and E-selectin).96,199 It was reported 
that AngII enhanced the expression of integrin alpha v beta 3, and that blocking 
antibodies to beta 3 attenuated AngII-induced adhesion in rat cardiac 
fibroblasts.104 AngII induced leukocyte adhesion in both arterioles and venules 
mediated by P-selectin and some other cell adhesion molecules. AngII increases 
integrin beta 2 expression in peritoneal cells.11 When elevated, MCP-1 (an 
important cytokine which is up-regulated by AngII) levels increased the CD11b 
positive monocyte/macrophage population in circulating blood of mouse.197 
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 AngII plays multiple roles in the regulation of MMPs. It was reported that 
an antagonist of the AT1 receptor, irbesartan, reduced prostaglandin E2 (PGE2)-
dependent MMP-2 activity, and this effect may in turn contribute to 
atherosclerotic plaque stabilization in humans.31 In cultured rat peritoneal 
macrophages, an increased MMP-2 expression and activity can be elicited by 
AngII and this increase was prevented by losartan, which is an antagonist of the 
AT1 receptor.121 AngII, through several pathways, might elicit an increase of 
MMP-2 activity indirectly. First, since the activity of pro-MMP-2 and pro-MMP-9 is 
upregulated by ROS produced by macrophage-derived foam cells,164 AngII might 
induce the activation of these MMPs through upregulating ROS production. 
Second, it was reported that osteopontin deficiency led to a decreased activity of 
both MMP-2 and MMP-9.20 This suggests that AngII may possibly increase MMP-
2 activation via up-regulating osteopontin. Third, TGF-beta is a MMP-2 
upregulator. When there is an AngII-induced increase of TGF-beta, the event 
may increase both expression and activation of MMP-2. Finally, it was reported 
that AngII-induced MMP-2 release from endothelial cells is mediated by TNF-
alpha,7 as well as that AngII increases TIMP-1 in rat VSMCs.24 
 Taken together, one of the major and unique advantages of using mice for 
experimental cardiovascular research is that it is possible to “knock out” or 
replace endogenous genes, thereby determining the influence of protein 
expression on the development of diseases. In this study, our hypothesis is that 
MMP-2 deficiency might reduce atherosclerosis and AngII-induced AAA 
development in an apoE deficient mouse model. 
 
II. Materials and Methods 
 
Animals 
 
 MMP-2 deficient mice (C57BL/6 background) were obtained from Dr. 
Itohara (Brain Science Institute, RIKEN, Saitam, Japan). ApoE-/- mice on a 
C57BL/6 background were obtained from the Jackson Laboratory (Bar Harbor, 
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ME, USA). All of the mice were housed under barrier conditions with normal 
laboratory diet and water ad libitum.  MMP-2-/- mice and apoE-/- mice were then 
bred and their offspring, generation F1 (MMP-2+/- x apoE+/-), were mated to 
produce littermates with the desired MMP-2+/+ and MMP-2-/- x apoE-/- mice 
genotypes (F2).  Male MMP-2+/+, +/- and -/- x apoE-/- littermates were used in 
all subsequent experiments. All procedures were performed with the approval of 
the University of Kentucky Institutional Animal Care and Use Committee. 
 
Experimental protocol 
 
 In order to address the issues raised by this specific aim, my experimental 
protocol will be, primarily, two-fold. First, to investigate AngII-induced AAAs and 
atherosclerosis in MMP-2+/+, +/-, and -/- x apoE-/-, I designed the experiment as 
follows: 
 
 
 
 Second, I will use 20 to 24-week-old male apoE-/- mice with various MMP-
2 genotypes to investigate atherosclerosis development in aged hyperlipidemic 
animals. These mice will be fed with normal laboratory diet and will not receive 
AngII infusion. 
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Polymerase chain reaction (PCR) for mouse genotyping 
 
 Genotyping for MMP-2 deficiency: PCR was performed using genomic 
DNA isolated from tail snip samples of mice using a DNeasy tissue kit (Qiagen 
Inc., Valencia, CA, USA). The exon1 of the MMP-2 gene was exchanged to 
reverse pgk-neo gene in MMP-2-/- mice. The amplification was performed using 
these specific primers: for the mutant allele, the forward primer recognized the 
DNA sequencing on the reverse pgk-neo gene (5'-
TGCAAAGCGCATGCTCCAGA-3'). The reverse primer recognized the DNA 
sequence on exon2 (5'-TGTATGTGATCTGGTTCTTG-3'). The amplicon is 1.1Kb 
(kilo-base pair) fragment. For the wild type allele, both primers recognize DNA 
sequences on the exon1 of MMP-2. The forward primer reads 5'-
CAACGATGGAGGCACGAGTG-3' and the reverse 5'-
GCCGGGGAACTTGATGATGG-3'. The amplicon is a 120bp (base pair) 
fragment. The information for these primers was kindly provided by Dr. Itoh 
(Institute for Virus Research, Kyoto, Japan). The thermocycling reactions were 
performed as follows: 35 cycles of denaturation at 94°C for 1 minute, annealing at 
57°C for 1 minute, extension at 72°C for 1 minute, followed by 1 cycle of final 
elongation at 72°C for 7 minutes. 
 Genotyping for ApoE deficiency: To detect the apoE deficiency, PCR 
was performed as described previously.160 The sequences of each primer were: 
5'-GCCGCCCCGACTGCATCT-3'; 5'-TGTGACTTGGGAGCTCTGCAGC-3';  and 
5'-GCCTAGCCGAGGGAGAGCCG-3'. Amplification of a single species of PCR 
product of 245 bp (mutant allele) and/or 155 bp (wild type allele) corresponded to 
a genotype. The thermocycling reactions were performed as follows: the initial 
denaturation at 94°C for 1 minute, followed by 35 cycles of denaturation at 94°C 
for 1 minute, annealing at 55°C for 1 minute, extension at 72°C for 1 minute, then 
followed by 1 cycle of final elongation at 72 °C for 5 minutes. 
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Gelatin zymography 
 
Gelatin zymography was performed to confirm the disruption of the MMP-
2 gene as described previously.83 Frozen segments of mouse aorta were 
homogenized in Rho-binding lysis buffer (RLB) containing Tris 50mM (pH7.2), 
NaCl (150mM), MgCl2 (10mM), 1% Triton X-100, 0.1% SDS and 0.5% Sodium 
deoxycholate for 30 minutes on ice. Following extraction, the homogenate was 
centrifuged at 13,000 x g for 10 minutes at 4 °C. The protein content was 
measured by a DC-protein assay kit (BioRad Lab., Hercules, CA, USA). A 7.5% 
SDS-polyacrylamide gel containing 2% gelatin was pre-run at 50 volts for 5 to10 
minutes. Protein extracts of aortas or lysis of mouse peritoneal macrophages 
(MPMs) (15µg) and an appropriate amount of 5x non-reduced loading dye were 
loaded onto the gel.   The gel was run at 50 volts until samples were through 
stacking gel, then the voltage was increased to 120 volts. After the 
electrophoresis, the gel was soaked in a 2.5% Triton X-100 solution for 1 hour at 
room temperature (RT) on a shaker to remove SDS. Then the gel was washed 
twice with distilled H2O (15 minutes per wash) at RT on a shaker. After washing, 
the gel was incubated overnight at 37°C in 50 mM Tris buffer containing either 5 
mM CaCl2 or 10 mM EDTA (negative control for MMP activity) on a shaker. Then 
gel was stained with Brilliant Blue R (Sigma, St. Louis, MO, USA) for 15 to 30 
minutes at RT. The gel was de-stained with 1x de-staining solution containing 1% 
glycerol, 7.5% acetic acid, 30% methanol, and 61.5% H2O, until clear bands 
appear. Bands of gelatin lysis by MMP-2 were quantified using a Kodak 440CF 
image station. 
 
AngII infusions and blood pressure measurement 
 
For AngII infusion, mice were anesthetized with sterile saline containing 
22.7% ketamine and 3.4% xylazine.  AngII (1,000 ng/kg/min) or saline was 
administered subcutaneously via Alzet osmotic minipumps (DURECT Corp., 
Cupertino, CA, USA) as described previously.37 
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 Systolic blood pressures were obtained from conscious mice using a 
computerized tail cuff method (BP-2000 Visitech Systems, Apex, NC,USA), as 
previously described.38 Mice were acclimated to the system for two weeks prior 
to the minipump implantation, and measurements were obtained at the same 
time of day throughout the study, 5 days per week. 
 
Peripheral white blood cell counting 
 
 Blood was obtained by retro-orbital bleeding of anaesthetized mice using 
micro-hematocrit capillary tubes (Fisher scientific, Pittsburgh, PA, USA) and was 
blown into microtainer tube with EDTA (Becton Dickinson & Co., Franklin Lakes, 
NJ, USA). Peripheral blood cells were measured using a Coulter counter 
(Beckman Coulter Inc. Miami, FL, USA). 
 
Serum lipids and lipoprotein determination 
 
 Mouse serum total cholesterol concentrations were determined with 
cholesterol enzymatic assay kits (Wako Chemical, Richmond, VA, USA). The 
results were read on a 96-well plate with a microplate reader (Bio-Rad Model 
550) at 490nm. 
 Lipoprotein cholesterol distributions were evaluated in individual serum 
samples (50 µl) from 5 to 7 mice in each group after fractionation by size 
exclusion chromatography on a single Superose 6 column.38 Fractions were 
collected and cholesterol concentrations were determined with an enzymatic 
based kit (Wako Chemicals USA Inc., VA, USA). The 96-well plates were read on 
the microplate reader at 490nm. 
 
Quantification of atherosclerosis 
 
 Quantification of lesions in aortic root sections: Atherosclerotic lesions 
were quantified in the aortic root as described previously.40 In brief, the upper 
 31
third portion of the heart was embedded and frozen in OCT (optimal cutting 
temperature) compound (Sakura Finetec USA Inc., Torrance, CA, USA).  The 
heart was then sectioned on a cryostat from the direction of the apex toward the 
aortic valves until the aortic valves or cusps were observed within the aortic 
sinus.  Beginning at this point, sections were cut at a thickness of 10 µm and 
collected sequentially on eight slides, 9 sections on each slide.  A total distance 
of approximately 800 µm was taken for analysis.  Sections were stained for 
neutral lipids using Oil Red O (Sigma), and counter stained with hematoxylin 
(Biomeda corp., Foster City, CA, USA).  Digital images were taken and lesions 
were analyzed using ImagePro software version 4.1 (Media Cybernetics, Silver 
Spring, MD, USA). 
 En Face quantification of atherosclerosis: The percentage of the 
intimal area covered by atherosclerotic lesion was quantified in the aortic arch as 
described previously.40 Aortas were fixed in 4% paraformaldehyde overnight. 
After the periadventitial fat and connective tissue around aortas was removed, 
aortas were cut and pinned on black paper placed over wax plates to expose the 
intimal surface. Digital images were captured and atherosclerosis was measured 
as a percentage of lesion area to total surface area using ImagePro software. 
 
Classification of AAAs 
 
 AngII-induced AAAs were classified into four classes based on a standard 
which is described previously.38 Type I AAA is  defined as having a dilated lumen 
in the supra-renal region of the aorta without thrombus. A Type II AAA is defined 
as remodeled tissue in the supra-renal region that contains thrombus. Type III 
AAA is defined as multiple aneurysms containing thrombus. The most severe 
occurrence is a Type IV AAA and is defined as rupture that leads to death of 
mouse (Figure 2.5). 
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Immunohistochemistry staining 
 
 Air-dried cryostat (8µm thick) sections were fixed in cold acetone for 10 
minutes, then were incubated with 1% hydrogen peroxide (H2O2) for 2-5 minutes 
at 37°C, then were incubated in 5% blocking serum for 15-30 minutes, and with 
respective antibodies: chicken anti-mouse MMP-2 (50µg/ml), MMP-14 (2.5µg/ml), 
and TIMP-2 (10µg/ml) antibodies (Aves Labs, Inc., Tigard, OR, USA). Respective 
pre-immune antibodies were used as negative controls. After washing, the 
sections were incubated in biotinylated rabbit anti-chicken secondary antibody 
(1:1,000; Jackson ImmunoResearch Lab Inc., West Grove, PA, USA). 
For macrophage staining, a rabbit anti-mouse macrophage antibody (1:1,000; 
Accurate Chemical & Scientific Corp., Westbury, NY, USA) was incubated for 15 
minutes at 40°C, then incubated in biotinylated goat anti-rabbit secondary 
antibodies (1:500; Vector Lab Inc., Burlingame, CA, USA). After washing, the 
sections were incubated in Elite Vectastain ABC solution (Vector Lab. Inc.) for 10 
minutes at 40°C, then washed with peroxidase enhancer buffer (Biomed Corp.), 
then incubated with peroxidase chromogen (AEC; Biomed Corp.). After washing, 
the slides were counter stained with hematoxylin and mounted with glycerol 
gelatin (Sigma diagnostic Inc.). 
 
Collagen staining using Gomori Trichrome 
 
 Sections (8 µm) of frozen tissue (aortic root) were fixed in cold acetone for 
10 minutes and washed with distilled water. The slides were incubated with bouin 
solution (a mixture of saturated picric acid (75 ml), 37-40% formaldehyde (25 ml), 
and glacial acetic acid (5 ml)) for 1 hour at 56°C. After washing with dH2O until 
yellow color disappears, the slides were incubated with working solution of 
Weigert hematoxylin containing equal amounts of solution A (a mixture of 
hematoxylin (0.5ml) and 95% alcohol (50 ml)) and solution B (a mixture of 
concentrated hydrochloric acid (5 ml), 29% ferric chloride solution (20 ml), and 
distilled H2O (47.5 ml)) for 10 min at RT. After rinsing with dH2O, the slides were 
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incubated with Gimori solution for 15 to 20 minutes, then differentiated in 0.5% 
acetic acid for 2 minutes at room temperature. After rinsing with ethanol, the 
slides were rinsed again with water and mounted with permanent mounting 
medium (H5000, Vector lab. Inc.). 
 
Statistics 
 
 One-way ANOVA was performed to test the equality of three or more 
means with one independent variable at one time by using variances. A 
Student’s t-test was used to test the difference between two groups. All of the 
statistical analyses were done with SigmaStat 2.03 software (SPSS Inc., 
Chicago, IL, USA). Values with P < 0.05 were considered statistically significant. 
 
III. Results 
 
Confirmation of the genotype of MMP-2 of mice 
 
 PCR was performed to examine the MMP-2 genotype of mice.  The 1.1 kb 
amplified DNA product of mutant allele was detected only in DNA from MMP-2-/- 
mice and not in the DNA from MMP-2 wild type control mice (Figure 2.1 A). 
Gelatin zymography of aortic extracts was performed to confirm MMP-2 
genotypes of mice. As predicted, the band of gelatin lysis by MMP-2 was not 
visualized in the extracts of aortas of MMP-2 deficient mice (Figure 2.1 B). 
 
Effects of MMP-2 deficiency on AngII-induced AAAs and atherosclerosis in 
hyperlipidemic mice 
 
 Effect on body and organ weight: MMP-2 -/- x apoE-/- mice showed a 
tendency to have lower body weight when compared with MMP-2 +/+ x apoE-/- 
mice before AngII infusion. However, there was not a statistically significant 
difference (P = 0.082). After AngII-infusion for 28 days, a significantly lower body 
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weight was observed in MMP-2 deficient mice as compared to MMP-2 wild type 
mice (P < 0.05; Table 2.1). No significant difference was detected between the 
body weight of MMP-2 +/- vs. either MMP-2 +/+ or -/- mice. There was a 
correspondingly lower weight of the spleens from MMP-2-/- mice as compared 
with spleens from MMP-2 +/- mice and MMP-2 +/+ mice at the end of the 
experiment (P < 0.013; Table 2.1). However, the ratio of spleen to body weight of 
these mice was similar. The livers of MMP-2-/- mice exhibited this trend as well, 
however statistical significance was not achieved. 
 Effect on blood pressure: Mini-pumps filled with AngII were implanted 
subcutaneously into mice. There was a significant increase of blood pressure 
caused by AngII infusion in all of the three groups of mice with various genotypes 
of MMP-2. However, no significant difference was detected among various MMP-
2 genotypes at both basal level and after AngII-infusion for 28 days (Table 2.1). 
The increase of blood pressure level induced by AngII-infusion was similar in 
each MMP-2 genotype mice group (MMP-2+/+ 33.5 ± 11.3 vs. +/- 43.0 ± 8.7 vs. -
/- 40.7 ± 2.6 mmHg). 
 The effect on serum cholesterol levels: Serum total cholesterol 
concentrations were measured. There was a tendency of lower total cholesterol 
(TC) level in MMP-2-/- mice compared with MMP-2 +/- and +/+ x apoE-/- mice (P 
= 0.064; Table 2.1). Lipoprotein distribution was measured using size exclusion 
chromatography. The curves of VLDL, LDL/IDL and HDL of mice with various 
MMP-2 genotypes were overlapped with no significant difference (Figure 2.2). 
The effect on atherosclerotic lesion area: The extent of atherosclerosis 
was quantified with both en face analysis of the aortic arch and sequential cross 
sectioning of the aortic root as described previously. Surprisingly, the area of 
atherosclerotic lesion was similar among mice with various MMP-2 genotypes. 
The percent atherosclerosis area on the intimal surface of aortic arch was 2.2 ± 
0.5% vs. 3.9 ± 1.6% vs. 3.1 ± 0.8% in MMP-2-/-, +/- and +/+ x apoE-/- mice, 
respectively (Figure 2.3). On the transverse sections of aortic root, the size of 
atherosclerotic plaque was 12.9 ± 5.7 x 10-3 mm2 vs. 3.9 ± 1.1 x 10-3 mm2 vs. 
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10.1 ± 3.8 x 10-3 mm2 in MMP-2-/-, +/- and +/+ x apoE-/- mice, respectively 
(Figure 2.4). 
 The effect on AngII-induced aneurysms: AngII infusion (1,000 
ng/kg/min) for 28 days generated AAAs in 50% of MMP-2 +/+ mice (3 out of 6), 
67% of MMP-2 +/- mice (6 out of 9) and 67% of MMP-2 -/- mice (4 out of 6), 
respectively (Figure 2.6). There was no statistical difference among the three 
groups. Two of MMP-2+/- mice died of AAA rupture at the 6th and 23rd day of 
AngII infusion, respectively. One MMP-2-/- mouse died of AAA rupture at the 
nineteenth day of AngII infusion. No AAA rupture occurred in MMP-2+/+ mice. 
Abdominal aortas were weighed to provide an index of AAA severity. The weight 
of abdominal aortas was similar in each MMP-2 genotype mice group (19.7 ± 6.1 
mg vs. 16.9 ± 3.3 mg vs. 18.2 ± 3.0 mg in MMP-2+/+, +/-, and -/- x apoE-/- mice, 
respectively; Figure 2.7). 
 
Effects of MMP-2 deficiency on atherosclerosis in 5 month-old ApoE-/- mice 
 
General parameters: There was not a significant difference in the body, 
liver or spleen weight among MMP-2+/+, MMP-2+/-, and MMP-2-/- x apoE-/- 
mice. Interestingly, the number of peripheral white blood cell (WBC) was 
dramatically raised in MMP-2-/- x apoE-/- mice as compared to MMP-2+/+ and 
+/- x apoE-/- mice (Table 2.2). 
The effect on atherosclerotic lesion area: The deficiency of MMP-2-/- 
did not decrease the size of atherosclerosis in AngII-infused apoE-/- mice: No 
protective effect from MMP-2 deficiency was detected concerning the size of 
atherosclerotic lesions. Actually, the size of atherosclerotic plaque tended to 
increase in MMP-2-/- apoE-/- mice (54.1 ± 20.5 x 10-3 mm2 vs. 11.0 ± 4.4 x10-3 
mm2 vs. 18.5 ± 15.3 x 10-3 mm2 of the lesion area on the transverse sections of 
aortic root in MMP-2-/-, +/-, and +/+, respectively; Figure 2.8). However, the 
difference was not statistically significant. Interestingly, the deletion of the MMP-2 
gene dramatically changed the cellular and ECM components of the 
atherosclerotic plaques. The histopathologic and immunohistochemical staining 
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demonstrated that collagen was increased as well as cellular content. Both 
macrophages and smooth muscle cells were reduced in plaques of MMP-2-/- 
mice as compared to plaques of MMP-2 wild type mice (Figure 2.9). 
Immunostaining also indicated a relative reduction of MMP-14 and TIMP-2 
expression in atherosclerotic lesion of MMP-2-/- x apoE-/- mice. 
 
IV. Discussion 
 
 Twelve-week-old MMP-2-/- x apoE-/- mice showed lower body weight as 
compared with MMP-2+/+ x apoE-/- mice. However, this difference in body 
weight was not detected in 5-month-old apoE-/- mice. It was reported that the 
inhibition of MMP-2 impairs adipose tissue growth via the formation of a collagen-
rich matrix cap in mice.123 On the basis of our data, we concluded that MMP-2 
deficiency might retard but not ablate the development of adipose tissue of apoE-
/- mice. In future study, the weight of adipose tissue should be measured. MMP-2 
deficiency did not influence AngII-induced hypertension in apoE-/- mice. 
 MMP-2 has been shown to degrade ECM components of the vascular wall 
and become highly activated in AAAs and atherosclerotic lesions. It was reported 
that MMP-2 deficient mice on a C57BL/6 background were resistant to CaCl2-
induced AAAs formation. 126 Thus, it was surprising that MMP-2 deficiency did not 
reduce the size of atherosclerotic lesions or the incidence of AngII-induced AAAs 
in apoE deficient mice. There are a few mechanisms that may account for this 
discrepancy. First, MMP-2 might be insignificant in the progression of AAAs and 
atherosclerosis and second, the increment of other pathogenic factors might 
overwhelm the beneficial effect of MMP-2 deficiency in apoE-/- mice. Several 
hypotheses might account for the latter mechanism. 
 MMP-2 deficiency might cause a compensatory over-expression of one or 
more other elastinases in MMP-2-/- mice. As mentioned previously, MMP-9, 
another member of gelatinase family, has been implicated in atherosclerosis and 
AAAs. An adaptive mechanism might be activated in MMP-2 deficient mice, thus 
increasing MMP-9 expression. 
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Another reason may be that AngII infusion might enhance the production 
of other elastinases. AngII is not only implicated in hypertension, but is also a 
potent pro-inflammatory factor that has significant atherogenic actions via 
multiple pathways. There are several mechanisms by which AngII may increase 
the activity of MMP-9 in the vessel wall. AngII is a potent stimulus for the 
generation of ROS,77,211 which upregulates MMP-9 activation in the vascular 
wall.164 Also, AngII induces activation of MMP-9 via upregulating osteopontin,199  
the deletion of which can cause a decrease in MMP-9 activity in apoE-/- mice.20 
Finally, AngII induces production of many inflammatory cytokines. Some of these 
cytokines, such as MCP-1, IL-1, TNF-alpha, may upregulate MMP-9 activity.30 
AngII upregulates the expression of many growth factors including IGF, 
TGF-beta, PDGF, and bFGF. These growth factors have been implicated in the 
pathogenesis of atherosclerosis. Furthermore, AngII induces production of 
adhesion molecules (including osteopontin, VCAM-1, ICAM-1 and E-selectin, 
integrin alpha v beta 3, integrin beta 2).11,104,199 Elevated MCP-1, an important 
cytokine that is upregulated by AngII, increases the CD11b positive 
monocyte/macrophage population in mouse models.197 
 Hyperlipidemia might increase the activity of MMPs other than MMP-2. 
There is plenty of evidence suggesting that lipid lowering by either low-
cholesterol diet or lipid-lowering drugs leads to reduced activity of MMPs, 
including MMP-9, reducing the extent of aortic dilation and increasing the stability 
of atherosclerotic plaques in animal models. 2,189 Furthermore, the 
hormone/cytokine-like anti-atherogenic effects of apoE on the surrounding cells 
of the vascular wall should be considered in the current experiment in which 
apoE null mice were used. It was realized that the anti-atherogenic roles of apoE 
are beyond the regulation of lipoprotein metabolism and transport. Although the 
mechanism is not completely understood, it was reported that apoE can 
suppress the activation and proliferation of T lymphocytes via inhibiting important 
signaling such as intracellular calcium accumulation and phosphatidylinositol 
(PDI) turnover. 90 As a consequence, apoE inhibits the production of interleukin 
(IL)-2.106 ApoE also inhibits SMC proliferation and migration via binding to 
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LRP.223 Therefore, besides leading to hyperlipidemia in the mouse model, the 
deficiency of apoE might exacerbate vascular diseases directly. 
 In summary, apoE deficiency and exogenous AngII might have synergetic 
or additive pro-atherogenic effects on the atherosclerosis, overwhelming any 
benefits the deletion of MMP-2 might create. Based on data from our non-AngII 
treated MMP-2-/- x apoE-/- mice, we concluded that apoE deficiency might 
negate any protective effects MMP-2 deficiency might provide in the initiation and 
maturation of atherogenesis. Interestingly, the cellular and ECM content of the 
atherosclerotic plaque were changed in MMP-2 deficient apoE-/- mice. This 
suggested that the cell infiltration and ECM degradation during the pathologic 
process of atherosclerosis were influenced by MMP-2 in spite of the possible 
upregulation of the cytokines, growth factors, and other proteinases in the 
vascular wall.  The less pronounced immunohistochemical staining of TIMP-2 
and MMP-14 might be due to the reduced cellular content in the plaques in MMP-
2-/- mice. Further study is required to quantify these changes and evaluate the 
significance of the difference. 
 The current findings of this study make it essential to investigate the 
phenotypic changes in the vascular wall and inflammatory cells of MMP-2 
deficient mice. The hypothesis, concerning increased expression of other MMPs, 
namely MMP-9, and the subsequent morphological changes in vascular wall and 
associated inflammatory cells in the absence of MMP-2, will be presented and 
evaluated in the next two chapters. 
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Table 2.1 General parameters of AngII-infused 12-week-old male apoE-/- mice 
with various MMP-2 genotypes 
 
Mouse MMP-2+/+ x apoE-/- 
MMP-2+/- 
x apoE-/- 
MMP-2-/- 
x apoE-/- 
Body weight before AngII 
infusion (g) 24.2 ± 0.9 24.4 ± 0.5 21.1 ± 1.7 
Body weight at the 28th 
day of AngII infusion (g) 26.1 ± 0.6 25.7 ± 0.5 23.3 ± 1.1* 
Body weight gain during 
AngII infusion (g) 2.0 ± 0.6 1.3 ± 0.4 2.2 ± 0.8 
Spleen weight (x10-2 g) 9.8 ± 0.3 9.9 ± 0.6 7.7 ± 0.5* 
Liver weight (g) 1.26 ± 0.05 1.15 ± 0.07 1.03 ± 0.08 
Spleen/body weight (%) 0.38 ± 0.02 0.38 ± 0.02 0.33 ± 0.01 
Liver/body weight (%) 4.8 ± 0.1 4.5 ± 0.3 4.4 ± 0.3 
Total cholesterol (mg/dl) 282 ± 12 230 ± 33 221 ± 12 
Blood pressure before 
AngII infusion (mmHg) 137 ± 10 124 ± 6 120 ± 4 
Blood pressure at the 28th 
day of AngII infusion 
(mmHg) 
159 ± 9† 167 ± 6† 161 ± 5† 
 
Data represent mean ± SEM for groups of 6-9 mice. 
*P<0.05 with respect to MMP-2+/+ x apoE-/- mice 
† P<0.05 with respect to mice before AngII infusion 
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Table 2.2 General parameters of 5-month-old male apoE-/- mice with various 
MMP-2 genotypes 
 
Mouse MMP-2+/+ x apoE-/- 
MMP-2+/- x 
apoE-/- 
MMP-2-/- x 
apoE-/- 
Body weight (g) 29.0 ± 1.0 30.6 ± 1.0 28.6 ± 0.7 
Spleen weight  
(x10-2 g) 10.2 ± 0.3 10.9 ± 1.5 14.8 ± 2.8 
Liver weight (g) 1.24 ± 0.08 1.24 ± 0.07 1.28 ± 0.06 
WBC (1x103 
cells/mm3) 7.1 ± 1.6 6.3 ± 0.6 13.1 ± 1.2* 
 
Data represent mean ± SEM for groups of 3-6 mice. 
*P<0.05 with respect to MMP-2+/+ x apoE-/- mice. 
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Figure 2.1 Confirmation of MMP-2 genotype of mice (A) Representive PCR 
for MMP-2 genotyping is shown. The 1.1 kb band (for mutant allele) was 
detected in DNA of MMP-2-/- mice and was completely absent in DNA of the wild 
type control mice. The 120 bp band (for wild type MMP-2 allele) was detected in 
DNA of wild type mice but not in DNA of MMP-2 -/- mice. (B) Gelatin zymography 
of extracts (15µg) of aortas of MMP-2+/+ and -/- x apoE-/- mice. No MMP-2 
expression was detected in MMP-2 deficient mice, whereas a prominent 72kDa 
band of gelatin lysis by MMP-2 was present in the MMP-2 wild type mice. 
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Figure 2.2 Effect of MMP-2 genotype and AngII infusion on the lipoprotein 
distribution of 12-week-old apoE-/- mice Lipoprotein distribution of mice was 
resolved using size exclusion chromatography, namely, fast performed lipid 
chromatography (FPLC). The curves of VLDL, LDL/IDL and HDL of the mice 
were overlapped. Points represent the means of 5-7 individual mice, and bars 
are SEM. 
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Figure 2.3 Effect of MMP-2 genotype on AngII-induced atherosclerosis on 
aortic arch of 12-week-old apoE-/- mice  The percentage of the intimal area 
covered by atherosclerotic lesion was quantified in the aortic arch. The aortas 
from mice that died from AAA rupture were not included. There was not a 
significant difference in atherosclerosis among apoE-/- mice with various MMP-2 
genotypes. Values obtained from individual mice are represented in open 
symbols, the means are depicted as closed symbols and SEM as bars. 
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Figure 2.4 Effect of MMP-2 genotype on AngII-induced atherosclerosis on 
aortic root of 12-week-old apoE-/- mice   Area of atherosclerosis was 
measured in the sections of aortic root of mice. Lesion area was determined in 
10 µm-thick sections at 80 µm intervals after Oil Red O staining. Values obtained 
from individual mice are represented in open symbols, the means are depicted 
as closed symbols and SEM as bars. 
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Figure 2.5 Classification of AngII-induced AAAs.  Type I AAAs is defined as 
dilated lumen in the supra-renal region of the aorta without thrombus. Type II 
AAAs is defined as remodeled tissue in the supra-renal region that contains 
thrombus. Type III AAAs is defined as multiple aneurysms containing thrombus. 
Type IV AAAs is defined as rupture of AAAs which led to death of mouse. 
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Figure 2.6 Effect of MMP-2 genotype on the incidence of AngII-induced 
aneurysms in 12-week-old apoE-/- mice Incidence of AAA in mice from each 
group (n=6-9/group). No significant difference was detected among mice with 
various MMP-2 genotypes. 
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Figure 2.7  Effect of MMP-2 genotype on the severity of AngII-induced 
aneurysms in 12-week-old apoE-/- mice  Abdominal aortas were isolated by 
cutting the aorta at the level of the diaphragm and the iliac bifurcation. The tissue 
was weighed to provide an index of AAA severity. No significant difference was 
detected among mice with various MMP-2 genotypes. Values obtained from 
individual mice are represented in open symbols, the means are shown as 
closed symbols and SEM as bars. These data do not include the tissue weight of 
three mice (two MMP-2+/- mice and one MMP-2-/- mouse) that died from AAA 
rupture during AngII infusion. 
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Figure 2.8 Effect of MMP-2 genotype on atherosclerosis in 5-month-old 
apoE-/-mice     Area of atherosclerosis was measured in the sections of aortic 
root of 5-month-old male mice. Lesion area was determined in 10 µm-thick 
sections at 80 µm intervals after Oil Red O staining. Values obtained from 
individual mice are represented in open symbols, the means are depicted as 
closed symbols and SEM as bars. 
 
 
 
 
 
 
 
 
 
 
 
 
 49
 
 
 
 
Figure 2.9 Histopathological and immunohistochemical pictures of 
atherosclerotic lesion on aortic root of 5-month-old apoE-/- mice Cross-
sections of the aortic root of 5-month-old male MMP-2+/+ x apoE-/- (A, C, E, G, I, 
K) and MMP-2-/- x apoE-/- (B, D, F, H, J, L) mice were stained with Oil Red O 
staining (A and B; 40x), Gomori trichrome staining (C and D; blue-collagen; red-
smooth muscle cells).  The sequential sections were used to do 
immunohistochemical staining for macrophages (E) and (F), MMP-2 (G) and (H), 
MMP-14 (I) and (J), and TIMP-2 (K) and (L). C-F and I-L: the detail of boxed area 
in the Oil Red O staining in A and B on sequential sections (200 x); Bars indicate 
50 µm. 
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Chapter Three 
Phenotypic Changes in MMP-2 Deficient Mice 
 
I. Background 
 
 Genetically engineered mice are widely used in the functional analysis of 
the genes involved in cardiovascular diseases. These mice provide ideal 
approaches to study the members of gene families that encode several 
isoenzymes and lack selective inhibitors and inducers. For example, the 
influence of MMPs in genetically modified mice was investigated in studies as 
mentioned previously (in Chapter 1). Despite the high level of specificity, 
sometimes genetic engineering leads to unexpected results. Some of these 
results may provide insight into new functions of genes, which have not been 
detected or anticipated based on previous pharmacological interventions. 
 Frequently, transgenic animals do not show obvious phenotypic changes. 
The normality of the animal might be due to the insignificance of the gene. 
However, this normality may also be due to the activation of an adaptive 
mechanism that effectively compensates for the loss of that specific gene. 
Therefore, a detailed functional and morphological analysis of the transgenic 
animal is considered an important issue for the correct evaluation of the gene. It 
should be kept in mind that in contrast to a pharmacological approach, which 
usually causes an acute intervention with too little time for an adaptive 
mechanism, a transgenic approach is more like a chronic intervention allowing 
the animal time to develop possible compensatory adaptations. 72 
 
MMP-2 gene mutation in humans 
 
 In humans, homoallelic MMP-2 mutation on chromosome 16q12-q22 
causes a loss of all three MMP-2 functional domains: the Zn2+ binding site 
catalytic domain, the three fibronectin type II-like domains and the hemopexin 
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domain. Consequently, MMP-2 activity is completely ablated. MMP-2 ablation is 
assumed to alleviate the bone absorption in arthritis since MMP-2 is assumed to 
be a pivotal enzyme for bone and extracellular matrix turnover. However, the 
paradox in affected individuals is that the absence of MMP-2 leads to an 
autosomal recessive disease that is characterized by an excessive reabsorption 
and destruction of bones and arthritis. The patients have a set of ‘vanishing bone 
syndromes’, in which the bones, primarily the bones of hands and feet, are 
severely reabsorbed and destructed. The patients also have chronic arthritis and 
subcutaneous nodules in the hands and feet. The underlying mechanism is 
unclear. There are a couple of hypotheses for the findings in these patients – 
1)there might be compensatory overproduction of other protease(s) in patients 
with MMP-2 gene mutant or 2) MMP-2 might be essential for processing of the 
inductive factor which is required for the activity of osteoblasts or the regulation 
of the activity of osteoclasts.134, 188 
 
MMP-2 gene deficiency in the mouse model 
 
 MMP-2 deficient mice were developed in 1998 for use in cancer research. 
It was soon discovered that MMP-2  reduced angiogenesis and tumor 
progression in these animals.97 Although some morphological changes (including 
a mild growth retardation and delayed mammary gland development) were 
evident, these mice were not known to mimic the human disease found in bones 
and joints.188 It was consistently reported that the inhibition of MMP-2 impairs 
adipose tissue growth via the formation of a collagen-rich matrix cap in mice.123 
Other phenotypic changes of MMP-2 deficient mice include: 1) a decreased 
allergen inhaling-induced lung inflammatory cell egression which increases 
susceptibility to asphyxiation,35  2) a significant reduction of endothelial 
outgrowth, corneal angiogenesis, 103  and extra-retinal neo-vascularization in 
oxygen-induced retinopathy,150  and 3) an early onset and severe experimental 
autoimmune encephalomyelitis due to an increase in MMP-9 expression and 
activity.53 
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 MMP-2 deficient mice were used in research of cardiovascular diseases 
as well. Some related findings conclude that targeted deletion of MMP-2 
attenuates cardiac rupture after experimental myocardial infarction 80,136 and 
reduces intimal hyperplasia in blood flow cessation in the carotid arteries.101,114 
As mentioned previously in this dissertation, MMP-2 null mice are resistant to 
CaCl2-induced AAAs.126 However, there is a shortage of literature investigating  
characteristics of the vascular wall and inflammatory cells of MMP-2 deficient 
mice.  Such an investigation is essential for an in-depth understanding of the role 
of MMP-2 in cardiovascular diseases. The surprising result we have obtained in 
our previous study (in Chapter 2) makes this investigation an even more 
important event. The genotypic characteristics of several MMP deficient mice are 
listed in Table 3.1. 
 
II. Materials and Methods 
 
Animals 
 
Six-week-old male mice on C57BL/6 background were obtained from The 
National Cancer Institute (NCI, Frederick, MD, USA). They were used as control 
mice to detect the morphological change in aortic wall of MMP-2 deficient mice. 
MMP-2 deficient mice (C57BL/6 background) were obtained from Dr. Itohara 
(Brain Science Institute, RIKEN, Saitam, Japan). 
ApoE-/- mice on a C57BL/6 background were obtained from the Jackson 
Laboratory (Bar Harbor, ME, USA). MMP-2-/- mice and apoE-/- mice were then 
bred and their offspring, generation F1 (MMP-2+/- x apoE+/-), were mated to 
produce littermates with the desired MMP-2+/+ and MMP-2-/- x apoE-/- mice 
genotypes (F2).  Male MMP-2+/+ and -/- x apoE-/- littermates were used in all 
subsequent experiments. All of the mice were housed under barrier conditions 
with normal laboratory diet and water ad libitum. All procedures were performed 
with the approval of the University of Kentucky Institutional Animal Care and Use 
Committee. 
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Elastin staining using Verhoeff’s iron hematoxylin 
 
Age and gender-matched MMP-2 -/- and wild type mice on C57BL/6 
background were sacrificed and infused with 4% paraformaldehyde via the left 
ventricle at stable pressure (approximate 100 mmHg) for 60 to 90 minutes. 
Fragments from the abdominal aorta directly above the renal artery branch were 
cut and frozen in O.C.T. compound. Sections (8 µm) of frozen aortas were 
stained in Verhoeff’s iron hematoxylin (a mixture of 5% hematoxylin in absolute 
alcohol (20 ml), 10% Ferric chloride (8 ml) and Verhoeff’s iodine (8 ml)) for 20 
minutes. Sections were differentiated in 2% ferric chloride.  When the nuclei and 
elastin fibers were still black, and the background was weakly stained, the 
staining was halted. The sections were washed in distilled water, then in 95% 
alcohol to remove the iodine coloration. The slides were rinsed in distilled water 
again and mounted with glycerol gelatin. 
 
Mouse peritoneal macrophage harvest 
 
 Age and gender-matched MMP-2 -/- and wild type mice on C57BL/6 
background  were anesthetized with sterile saline containing 22.7% ketamine 
3.4% xylazine, then a cervical dislocation were performed. A slit was made in the 
outer skin in order to provide a “window” of visibility to the peritoneum. Sterile 
saline (5 ml) was injected into the peritoneal cavity through the intact abdominal 
musculature then slowly withdrawn through the same syringe needle. Fluid and 
cells were transferred into a 15 ml conical tube on ice. After centrifuging at 1,000 
x rpm for 5 minutes at RT, the supernatant was discarded. If there were RBCs 
visually detectable, 5ml of red blood cell (RBC) lysing solution containing 0.83% 
ammonium chloride and 0.158% Tris HCl (Sigma) was added into the tube. After 
2 to 5 minutes, cells were spun down at 1,000 x rpm for 5 minutes. The 
supernatant was discarded. The cells were lysed again if RBCs were still 
present. After lysis, RIPA buffer (100 ml) containing 1% NP-40, 0.5% sodium 
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deoxycholate, 0.1% SDS, 0.001% aprotinin, 1mM sodium orthovanadate, and 
0.01% PMSF (phenylmethyl sulfonyl fluoride) was added into each tube. The 
cells were incubated for 30 minutes on ice then transferred into microfuge tubes. 
The tubes were centrifuged at 13,000 x g for 10 minutes at 4°C. The supernatant 
was collected, and stored at -20°C. The protein content was measured using a 
micro BCA protein assay kit (Pierce, Rockford, IL, USA). 
 
Gelatin zymography 
 
 Age and gender-matched MMP-2-/- x apoE-/- and MMP-2+/+ x apoE-/- 
mice were sacrificed. Frozen aortas (from aortic arch to the iliac bifurcation) were 
homogenized. Gelatin zymography was performed as described previously in 
Chapter 2.  In this study, we compared the expression of MMP-9 in aortic 
extracts of these mice. Age and gender-matched MMP-2 -/- and wild type mice 
on C57BL/6 background were sacrificed and peritoneal macrophages were 
isolated as described above. Gelatin zymography was performed to compare the 
expression of MMP-9 in peritoneal macrophages. The MMP-9 level in aorta 
extracts of these mice was measured as well. 
 
Peripheral white blood cell counting 
 
 Age and gender-matched MMP-2 -/- and wild type mice on C57BL/6 
background were sacrificed. The experiment was performed as described 
previously (in Chapter 2). 
 
Statistics 
 
 Student’s t-test was used to test the difference between two groups. All of 
the statistical analyses as above were done by a SigmaStat 2.03 software. 
Values with P < 0.05 were considered statistically significant. 
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III. Results 
 
MMP-2-/- mice have lower body weights 
 
 Age-matched male MMP-2 deficient mice have a lower body weight as 
compared to MMP-2 wild type mice (n = 7/group; P < 0.01). Corresponding to the 
lower body weight, the weight of the spleens, livers and hearts of MMP-2 -/- mice 
were lower as well. However, no difference was detected in the heart/body 
weight and liver/body weight ratios of MMP-2+/+ and -/- mice (Table 3.2). We 
also observed that MMP-2 deficient mice have flatter faces and noses (Figure 
3.1), as well as shorter tails than their wild type counterparts. Although MMP-2 is 
involved in ovulation, the reproductive ability of MMP-2 mice appears normal (8-
10 pups per litter). 
 
MMP-2-/- mice have a higher peripheral WBC count 
 
 Blood was collected from mice (n = 10 -11/group). The MMP-2 genotype 
did not create any significant differences in the number of red blood cell, 
platelets, or concentration of hemoglobin. Interestingly, the number of WBC was 
dramatically raised in MMP-2-/- mice (12.2 ± 1.5 x 103 cell/mm3) when compared 
with MMP-2+/+ mice (6.5 ± 0.6 x 103 cell/mm3; P < 0.05; Figure 3.2). 
 
MMP-2-/- mice have increased branching of the elastin fibers in the 
abdominal region of the aorta 
 
 Sections of abdominal aorta from six-month-old wild type and MMP-2-/- 
male mice were stained with Verhoeff’s iron hematoxylin (n = 9-10/group). 
Branches of elastin fibers in the aortic walls were counted. An increased level of 
branching was observed in aortas from MMP-2-/- mice compared with aortas 
from MMP-2+/+ mice. (19.44 ± 1.07/section vs. 6.9 ± 1.13 per section; P < 0.05; 
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Figure 3.3) 
 
MMP-2-/- x apoE-/- mice have increased MMP-9 levels in aortic extracts 
 
 Gelatin zymography of aortic extracts from age and gender matched 
MMP-2+/+ and MMP-2-/- x apoE-/- mice was performed. The average band 
intensity from gelatin lysis by MMP-9 was increased 143% in the extracts of 
aortas of MMP-2 deficient mice compared with the aortas of MMP-2 +/+ (P < 
0.01; Figure 3.4). We also sought to determine the MMP-9 level in MMP-2-/- and 
MMP-2+/+ mice on a C57BL/6 background (apoE+/+). However, the expression 
of MMP-9 in these aortas was too low to be detected by gelatin zymography 
(data not shown). 
 
MMP-9 expression tends to increase in MMP-2-/- peritoneal macrophages 
 
 Gelatin zymography of peritoneal macrophage extracts from age-matched 
male MMP-2 wild type and MMP-2 deficient mice was performed. The average 
intensity of bands of gelatin lysis by MMP-9 was increased 98% in the extracts of 
aortas of MMP-2 deficient mice compared with aortas of MMP-2 wild type mice. 
However, there was no statistical significance (P = 0.2; Figure 3.5). 
 
IV. Discussion 
 
 MMP-2 null mice show some phenotypic differences when compared to 
their MMP-2 wild type counterparts, although these differences are less dramatic 
than those associated with MMP-14 null mice, which have severe bone and 
connective tissue abnormalities, inadequate collagen turnover and early 
postnatal death 85 (Table 3.1). 
 In our current study, we observed that MMP-2 deficient mice have lower 
body weight, flatter faces (noses) and shorter tails than their MMP-2 wild type 
counterparts. This might be due to a mild abnormality in the development of 
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connective tissues, such as bone, cartilage, and adipose tissue.  We were 
surprised to observe that MMP-2 deficient mice exhibited a similar size of 
atherosclerotic lesion and a similar incidence of AngII-induced AAA in a 
hyperlipidemic mouse model (see Chapter 2). Therefore, we did several 
experiments to determine the underlying mechanisms. 
 We confirmed the genotype of MMP-2 deficiency in the knockout mice by 
gelatin zymography.  The ablation of the MMP-2 phenotype allowed us to 
concentrate on the peripheral pathways. We measured blood pressure to 
examine the hemodynamic conditions present in the MMP-2 deficient mouse. 
Pressures for both knockout and control mice under both basal conditions and 
AngII infusion were consistent with previous findings.  We then compared the 
aortic wall structure of MMP-2 -/- and +/+ mice. Interestingly, we observed an 
increased number of branches in elastin fibers of the aorta of MMP-2 null mice 
compared with aorta of wild type mice. This may provide protection from AAAs by 
strengthening the vascular wall. It also may signal the destruction and 
remodeling of ECM, and increased rigidity of vascular wall. Future study is 
required to measure the vascular contractility of MMP-2-/- mice. 
 MMP-2-/- x apoE-/- mice consistently expressed elevated levels of MMP-9 
in aortic tissue extracts as compared to wild type controls, as determined by 
gelatin zymography.  However, in aortas of MMP-2-/- mice on a C57BL/6 wild 
type background (apoE+/+) and MMP-2 wild type control mice, the MMP-9 level 
was too low to be detected by gelatin zymography (data not shown). This 
indicates that hyperlipidemia might be involved in the compensatory 
overexpression of MMP-9 in apoE-/- mice. Another potential mechanism 
underlying this compensation is that MMP-2 might be required to regulate the 
expression and/or activation of other elastinases. Recently, it was reported that 
the MT1-MMP/TIMP-2/MMP-2 complex, in addition to facilitating the activation of 
pro-MMP-2, could be involved in regulating the expression of MMP-9 in 
lymphocytes of mice.53 MMP-2 deficient mice showed a tendency to have higher 
MMP-9 expression in peritoneal macrophages as compared to wild type control 
mice. However, there was not a statistical significance. 
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 In addition, we detected a significant increase in peripheral white blood 
cell (WBC) number in MMP-2 null mice. Infection, leukemia and tissue damage 
are the three most common reasons for a high WBC count and secondary 
immunodeficiency. However, splenomegaly, which is an important sign of 
infection, is not observed in MMP-2 deficient mice. One study has been 
published that studied the role of MMP-2 expression in clinical course of acute 
myeloid leukemia (AML). It surprisingly showed that 82% of the MMP-2 positive 
patients survived for over 3 years, whereas all MMP-2 negative patients relapsed 
within 13.5 months of diagnosis.113 Compared to solid tumors, this finding is 
surprising, as increased MMP-2 expression in solid tumors is often related with a 
more biological aggressive and invasive phenotype.41,81,142  However, the role of 
MMPs in increased angiogenesis and leukemic cell growth have not been 
extensively investigated. Further studies need to be completed to determine the 
mechanism underlying the high peripheral WBC number of MMP-2 null mice. 
 Our studies identified phenotypic changes in the aortic vessel wall and 
peripheral white blood cells of MMP-2 null mice. Many of these changes are 
currently unexplained and further investigation may bring insight into the broader 
biological role of MMP-2. These data support that MMP-2 plays a complex role 
beyond degradation of ECM in vascular diseases. 
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Table 3.1 Phenotypes of transgenic mice lacking MMP-2, MMP-9, MMP-14 and 
TIMP-2 genes 
 
Gene 
deficiency Phenotypes 
MMP-2 Mild growth retardation and delayed mammary gland 
development 190 
reduced intimal hyperplasia in a mouse carotid artery 
blood flow cessation model 101,114 
Reduced AAA formation induced by abluminal 
application of calcium chloride in mice10 
MMP-9 Resistant to aneurysms induced by elastinase infusion 
and abluminal application of CaCl210,162 
Prolonged contact dermatitis199 
Defective osteoclast recruitment 52 
MMP-14 Reduced collagen turnover 
Impaired endochondral ossification and angiogenesis; 
Death before the onset of sexual maturity83,222 
Severe postnatal growth-retardation and skeletal          
abnormalities212 
TIMP-2 Deficient MMP-2 activation212 
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Table 3.2 Body and organ weight of 6-week-old male MMP-2+/+ and -/- mice 
 
Mouse MMP-2 +/+ MMP-2 -/- 
Body weight (g) 22.4 ± 0.6 18.4 ± 0.9* 
Spleen weight (x10-2 g) 7.9 ± 0.3 6.7 ± 0.5* 
Spleen/body weight (%) 0.35 ± 0.01 0.36 ± 0.02 
Liver weight (g) 1.30 ± 0.04 0.98 ± 0.10* 
Liver/body weight (%) 5.8 ± 0.2 5.3 ± 0.4 
 
Data represent mean ± SEM for groups of 7 mice. 
*P<0.05 with respect to MMP-2 +/+ mice 
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Figure 3.1  Craniofacial differences between MMP-2 +/+ and MMP-2 -/- mice.  
Representative pictures of a MMP-2+/+ and -/- mouse were taken while subjects 
were anaesthetized. The MMP-2 deficient mouse (on the right) has a depressed 
face and shorter nose than the MMP-2 wild type mouse. 
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Figure 3.2  Peripheral WBC counts from MMP-2 -/- and MMP-2 +/+ mice. 
Blood was obtained by retro-orbital bleeding and the cells were counted using a 
Coulter counter (n=10-11/group). Histobars represent the means and bars are 
SEM. (*P < 0.01 for comparisons of MMP-2 deficient mice versus wild type mice) 
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Figure 3.3 Morphological changes in the aortic wall of MMP-2 -/- and MMP-2 
+/+ mice  (A and B) Representative sections of elastin staining using Verhoeff’s 
iron hematoxylin of abdominal aortas from six-month-old male MMP-2+/+ and -/-. 
Arrows indicate branches of elastin fibers. (C) The number of elastin fiber 
branches counted in each section. Values obtained from individual mice are 
represented as open circles, means are depicted as closed diamonds and SEM 
as bars. (n = 9-10/group; *P < 0.05 for comparisons of MMP2+/+ versus -/- mice) 
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Figure 3.4  Aortic extract expression of MMP-9 in MMP-2-/- and MMP-2+/+ x 
apoE-/- mice. (A) Gelatin zymography of protein extracts from mouse aortas.  
(B) Gelatinase activity was quantified by densitometry. Data were obtained from 
3 individual mice. Histobars represent the means and bars are SEM. (*P < 0.05 
for comparison of MMP-2 deficient versus MMP-2 wild type aortas) 
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Figure 3.5  Mouse peritoneal macrophage expression of MMP-9 in MMP-2 -/- 
and MMP-2 +/+ x apoE-/- mice. (A) Gelatin zymography of protein extracts of 
macrophages. Protein extracts (15µg in each line) from aortas of MMP-2 wild 
type or MMP-2 deficient apoE-/- mice.  (B) Gelatinase activity was quantified by 
densitometry. Data were obtained from 4 individual mice. However, there was not 
a statistical significance (P = 0.2). Histobars represent the means and bars are 
SEM. 
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Chapter Four 
 
Reduced Adhesion Ability and Integrin Beta 3 Expression in 
MMP-2 Deficient Macrophages (in vitro) 
 
I. Background 
 
 The recruitment of inflammatory cells from the circulation and their trans-
endothelial migration into the vascular wall are prominent features in both 
atherosclerosis and AAAs. There are considerable new insights into the 
mechanism underlying the recruitment of inflammatory cells. The initiating step of 
this process might be the random contact of inflammatory cells to the 
endothelium, followed by cell-rolling, -tethering, -arresting, and cell-
transmigrating through the endothelium. Adhesion molecules/receptors, including 
selectins, immunoglobin-like molecules (such as ICAM, VCAM, and PECAM), 
cadherins, and integrins are involved in this process. 68, 93, 94 
 As mentioned previously, many types of cells in the vascular wall including 
endothelial cells, VSMCs, and fibroblasts, produce MMP-2 constitutively. 
Inflammatory cells, such as macrophages, T lymphocytes, and mast cells, 
produce MMP-2 as well. Unlike the mesenchymal cells, inflammatory cells 
produce MMP-2 in a relative small amount.  During the occurrence of 
inflammation, including vascular diseases, pathophysiological changes might 
modify the production of MMP-2 by inflammatory cells. For instance, secretion of 
MMP-2 by T lymphocytes can be upregulated by an interaction between the cell 
and fibronectin through alpha 4 beta 1 integrins, as well as a ligation of VCAM-
1.216 The expression of macrophage-derived MMP-2, which is not as abundant 
as macrophage-derived MMP-9, was significantly reduced in CCR-2 deficient 
mice.153 In cultured rat peritoneal macrophages, an increased MMP-2 expression 
and activity can be elicited by AngII and subsequently prevented by losartan, an 
AT1 receptor antagonist.121 As mentioned in Chapter 1, most MMPs are secreted 
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as zymogens and are not activated spontaneously. It is thought that MMPs 
secreted by macrophages could serve as activators of MMPs derived from other 
cell types, including VSMCs.147 
 
The potential role of MMP-2 in the regulation of macrophage behavior and 
cell-matrix interaction 
 
 MMP-2 activity might influence the behavior of inflammatory cells, playing  
a pivotal role in cardiovascular diseases. There is evidence that MMP-2 is able to 
facilitate neutrophil-endothelial cell adhesion by cleaving pro-endothelin into an 
active form in vitro. 58 Furthermore, it was reported that degradation fragments of 
ECM components, generated by the action of MMP-2, are involved in 
macrophage migration in a myocardial infarction mouse model.136 As mentioned 
in Chapter 1, ECM proteins may bind to cytokine receptors, growth factor 
receptors and cell-adhesion receptors thus transducing receptor-mediated 
signalings, which are important for regulating biological functions of the cell, 
including mobility, proliferation, and apoptosis. Meanwhile, the binding of ECM 
proteins may influence cell behavior by influencing the binding of other ligands to 
these receptors. 
 Integrins are the major receptors mediating cell-to-ECM and cell-to-cell 
adhesion. They have been studied extensively, becoming the most-understood 
cell adhesion receptors.47   The integrin family is comprised of 24 members. Each 
member is categorized as a heterodimeric transmembrane glycoprotein, 
containing one of 18 alpha and one of 8 beta subunits. Differentiation is achieved 
by the unique, non-covalent coupling of these subunits. Integrins mediate cell 
adhesion by activating a variety of protein tyrosine kinases like focal adhesion 
kinase (FAK) and Src-family kinases. Integrins also initiate intracellular signaling 
molecules which control cell shape, migration, proliferation, differentiation and 
survival.68 In adherent cells, integrins are apparently in a constitutively active 
form which is induced by inside-out signaling events such as Rho-like GTPase, 
certain cations (e.g. Mn2+), and antibodies (Figure 4.1). This ligand binding at the 
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cytoplasmic domain of integrins changes their conformation from inactive to 
active form by splitting away the alpha subunit, which allows the interaction of 
beta subunit with the cyto-skeletal components. In the active conformation, the 
affinity of integrin and its ligands is enhanced, therefore, the outside-in signaling 
pathway can be turned on and modulate cell behaviors. 36,48,88 Although the 
mechanism underlying the regulation of integrin-mediated cell adhesion is 
unclear, it is clear that integrin-mediated cell spreading leads to increased 
adhesion. 
 Cell migration is a process that also requires the strict regulation of 
integrin-mediated adhesion and release of the adhesive cell. A net movement of 
the cell is due to the cooperation of two elements: 1) the repeated cycle of the 
assembly and disassembly of adhesive complexes which leads to the protrusion 
of the cell membrane at the front part and 2) the cyto-skeletal contraction and 
detachment of the cell rear part. There is evidence that a pool of integrins is 
internalized and recycled to the rear part of the cell, demonstrated by rear- 
ligand-bound integrins left behind on the surface of substrate. 17,155,168 
Furthermore, the interaction between integrins might affect cell migration and 
surface expression levels of these molecules, causing a “clustering” of integrins, 
which may influence the affinity of both integrins and their ligands.205 The 
interactions between integrins and receptor kinases such as the EGF and the 
PDGF receptors have also been reported. These interactions could lead to the 
clustering of growth factor receptors, thereby enhancing the downstream-
signalings.60 
 Like other integrins, integrin alpha v beta 3, is involved in cell adhesion, 
migration and survival.19,175,204 As mentioned in Chapter 1, alpha v beta 3 integrin 
also functions as an anchor protein of MMP-2 on the cell surface, becoming 
involved in MMP-2 activation. Integrin alpha v beta 3 is expressed by many cell 
types, including macrophages, endothelial, smooth muscle, fibroblasts, 
osteoclasts, and others.133 It associates with a variety of ECM proteins such as 
vitronectin, osteopontin, fibronectin, fibrinogen, thrombospondin, proteolysed 
collagen, and von Willebrand factor. It also associates with some important cell 
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surface molecules including MMP-14, MMP-2, VEGFR2, IAP, and 
CD47.46,82,86,187,212 The expression of integrin alpha v beta 3 on endothelial cells 
was found to increase when nitric oxide (NO) levels were increased in rat cardiac 
fibroblasts. Related to this, the blocking antibodies to beta 3 attenuated AngII-
induced adhesion in rat cardiac fibroblasts.104,116 Another study reported that 
blocking integrin alpha v beta 3 inhibits macrophage adhesion and migration.214 
Pharmacological blockade of the integrin alpha v beta 3 inhibits angiogenesis in 
cancer and rheumatoid arthritis patients.23 Furthermore, an organic molecule 
(TSRI265) which selectively blocks integrin alpha v beta 3 interaction with MMP-
2 without influencing MMP-2 activity, inhibits angiogenesis and tumor growth in 
nude mice.19,184  It was also reported that alpha v beta 3 integrin regulated 
macrophage foam cell formation, possibly influencing the progression of 
atherosclerosis in humans.6 
 In this study, we sought to investigate the influence of MMP-2 deficiency 
on certain cell behaviors found in mouse peritoneal macrophages. We also 
sought to examine the potential effects of the interaction between MMP-2 and 
integrin alpha v beta 3 on macrophage behavior. 
 
II. Materials and Methods 
 
Adhesion assay of peritoneal macrophages 
 
 Peritoneal macrophages were collected from six to eight-week-old MMP-
2+/+ and MMP-2-/- male mice as described previously (see Chapter 3) and 
plated (4 x 105 cells/well) in collagen I-coated 24-well plates (Becton Dickinson, 
Bedford, MA, USA). Cells were incubated in serum free DMEM media (800 
µl/well) at 37 oC for 30 minutes in a humidified incubator containing 95% air and 
5% CO2. The MPMs were then washed 3 times with serum free DMEM media. 
Attached cells were either stained with hematoxylin for cell counting, or 
harvested and lysed to measure the protein content using a micro BCA protein 
assay kit as described previously (Chapter 3). Cell counting was performed using 
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ImagePro software. Six independent fields from each well (5 wells for each 
group) were analyzed using a light microscope at a magnification of 100X. 
 For controls, peritoneal macrophages from 6-week-old C57BL/6 mice 
were harvested and incubated with 10µM TSRI265 (Calbiochem, San Diego, CA) 
in DMEM containing 10% serum replacement (heat-treated bovine albumin and 
insulin, without MMP-2 and 9; Sigma) at 37 oC for 3 hours in a humidified 
incubator containing 95% air and 5% CO2. This compound is a known disruptor 
of MMP-2 binding to integrin alpha v beta 3 without influencing MMP-2 activation.  
After three washings with serum free media, the cells were harvested and lysed 
for protein content, measured using a micro BCA protein assay kit as described 
previously. 
 
Invasion assay of peritoneal macrophages 
 
 Peritoneal macrophages were collected from six to eight-week-old wild 
type mice as described previously (Chapter 3). A twenty four-well matrigel 
invasion chamber (BD Biosciences, San Diego, CA, USA) was used. The upper 
chambers contained a matrigel layer and a microporous filter (8 µm pore 
diameter). Either no serum or 10% FBS in DMEM 750µl was added in the bottom 
chambers. Macrophages (4 x 105/well) were seeded on the upper chamber in 
500µl οf DMEM  containing 10% serum replacement either with or without 
TSRI265 (10µM) and incubated at 37 oC for 18 hours in a humidified incubator 
containing 95% air and 5% CO2. The cells that migrated to the lower chamber 
were fixed and stained with hematoxylin and counted as described above. 
 
RT-PCR 
 
 mRNA was isolated from peritoneal macrophages using a mRNA isolation 
kit (Promega, Madison, WI, USA). The primer sequences of integrin beta 3 are: 
forward 5’-GGGGACTGCCTGTGTGACTC-3 and reverse 5’ 
CTTTTCGGTCGTGGATGGTG-3’.15 The conditions of the cycling reactions are 
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as follows: 40 cycles of denaturation at 94°C for 30 seconds, annealing at 58.1°C 
for 1minute, extension at 68°C for 2 minutes, followed by 1 cycle of elongation at 
68°C for 2 minutes. The mRNA signals of beta actin were used as loading 
controls. The primer sequences of beta actin are: forward 5'-
GAGACCTTCAACACCCC-3' and reverse 5'-GTGGTGGTGAAGCTGTAG-3'.39 
The conditions of cycling reactions are: 40 cycles of denaturation at 94°C for 30 
seconds, annealing at 60°C for 1minute, extension at 68°C for 2 minutes, 
followed by 1 cycle of elongation at 68°C for 2 minutes. 
 
Immunofluorescence staining for integrin beta3 (CD61) in MPMs 
 
 Peritoneal macrophages of MMP-2 deficient and wild type mice were 
cultured in an 8-well Lab-Tek chamber slide (0.3 x 106/well) in serum free DMEM 
for 3 hours. The media was deleted and the cells were fixed in cold acetone for 
10 minutes. After fixation, the cells were washed twice with 1x PBS.  Cells were 
incubated with 15% goat serum for 3 hours at room temperature or overnight at 
4º C to block the non-specific reaction, then incubated with purified hamster anti-
mouse CD61 (integrin beta3) antibody (1: 20; 2C9.G2; BD Pharmingen, San 
Diego, CA, USA) overnight at 4°C. After washing 5 times with 1x PBS, the cells 
were incubated with Alexa Fluor 488 conjugated goat anti-hamster secondary 
antibody (1: 500; A-21110; Molecular Probes, Eugene, OR, USA) for 30 minutes 
at RT. The cells were washed 8 times with 1xPBS. The genomic nuclei were 
counterstained with Hoechst 33258 (1µg/ml) for 5-10 minutes. The chamber was 
removed. The slides were mounted with gel/mount (Catalog number M01, 
Biomed, Foster City, CA, USA). Images were captured digitally by a fluorescence 
microscope (Nikon eclipse E600, Japan) with exposure times kept constant. 
 
Flow cytometry of integrin beta 3 for MPMs 
 
 Mouse peritoneal macrophages (1x106 cells/ml/ FACS tube) were 
incubated with purified rat anti-mouse CD16/CD32 monoclonal antibody (1:100, 
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30µl/0.02µg/106 cells; BD Pharmingen) in 1mM EDTA containing Hank’s media 
or 1xPBS/0.5% BSA for 15-30 minutes at 4°C. This reduces the Fc receptor-
mediated binding by antibodies of interest. The cells were incubated with R-
Phycoerythrin (R-PE)-conjugated rat anti-mouse CD11b (1:20, 2µl/0.02µg/106 
cells) and fluorescein isothiocyanate (FITC)-conjugated hamster anti-mouse 
CD61 (2µl /1µg/106 cells) monoclonal antibody (BD Pharmingen) for 30 minutes 
on a rocker at 4°C. Cells were then centrifuged at 1,000x rpm for 5 minutes at 4° 
C and the supernatant aspirated. After washing twice with 2.0 ml washing buffer 
(1xPBS/0.5% BSA), the cells were re-suspended in 250µl sterile FACS tubes 
with 1 x PBS solution. Immunofluorescence was analyzed with a flow cytometer. 
 
Statistics 
 
 Data are presented as means ± SEM. One-way ANOVA was performed to 
test the equality of three or more means with one independent variable at one 
time by using variances. Student’s t-test was used to test the difference between 
two groups. All of the statistical analyses above were done with SigmaStat 2.03 
software. P values < 0.05 were considered statistically significant. 
 
III. Results 
 
Disruption in the binding of MMP-2 to integrin alpha v beta 3 reduces 
peritoneal macrophage invasion but not adhesion 
 
 We sought to determine the influence of the interaction between MMP-2 
and integrin alpha v beta 3 mouse peritoneal macrophages on the certain cell 
behavior, particularly adhesion and invasion. Application of TSRI265, a disruptor 
of MMP-2 binding to integrin alpha v beta 3, led to a 53 percent reduction in 
macrophage invasion through matrigel when compared to the non-treated cells 
(P < 0.01; Figure 4.2). The lower chambers, containing serum free media, were 
used as controls.  The protein amounts from attached cells were also measured 
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after incubating with TSRI265 (10µM) for 3 hours and washing. However, no 
significant change in cell adhesion was detected (P = 0.106; Figure 4.3). 
 
Peritoneal macrophages from MMP-2 -/- mice have reduced adhesion 
activity 
 
 In this experiment, we sought to examine the migration activity of 
peritoneal macrophages of MMP-2 deficient mice. The cell adhesion assay was 
performed. We observed a reduction in cell migration that might be due to the 
reduced adhesion ability of MMP-2 deficient macrophages.  Peritoneal 
macrophages were collected from eight-week-old male MMP-2+/+ and -/- mice 
(n = 3-5/group). After culturing (30 minutes) and washing, the attached cell 
number of MMP-2-/- macrophages was significantly less compared to the cell 
number of wild type macrophages (51.8 ± 16.3/well vs.770.2 ± 126.5/well; P < 
0.001). To confirm this data, after washing, the attached cells were collected and 
lysed. The protein content of the cell lysate was measured. Correspondingly, we 
observed that the protein concentration from the cell lysate of MMP-2 deficient 
macrophages was 57% lower than the protein concentration from wild type 
macrophage cultures (P < 0.001). The experiment was repeated without culturing 
or washing, and the protein content of wild type and MMP-2-/- macrophages was 
found to be similar (Figure 4.4). 
 
Peritoneal macrophages from MMP-2 -/- mice have reduced integrin beta 3 
expression 
 
 We measured integrin beta3 expression in mouse peritoneal 
macrophages with RT-PCR and immunofluorescence staining. These techniques 
demonstrated that the mRNA level of integrin beta 3 was reduced by 58% in 
peritoneal macrophages of MMP-2-/- mice (P < 0.05; Figure 4.5). 
Immunofluorescence staining and flow cytometry demonstrated a significant 
reduction of integrin beta 3 expression in MMP-2 deficient peritoneal 
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macrophages as well (P < 0.05; Figure 4.6; 4.7). These data suggest that the 
reduced adhesion, which was observed in MMP-2 deficient macrophages, might 
be due to the reduced expression of integrin beta 3, but not be due to the 
absence of interaction between these two proteins. 
 
IV. Discussion 
 
 The recruitment of macrophages is a common and prominent 
characteristic of both AAA and atherosclerotic tissue. In these diseases, the 
invasion of macrophages and release of cytokines and proteolytic enzymes are 
critical in the initiation and progression of vascular remodeling. Cell adhesion is 
the initial step in the trans-mural infiltration of macrophages. Integrins are the 
pivotal receptors that mediate cell-to-ECM and cell-to-cell adhesion. In particular, 
integrin alpha v beta 3 facilitates the activation of MMP-2 by localizing pro-MMP-
2 on the cell surface. 
 There is evidence that the expression and activation of integrin alpha v 
beta 3 can not only correlate with other cell types, such as invasive tumor cells, 
but also correlate with the activation of MMP-2 and MMP-14.26,184 The binding 
ability of MMP-2 to integrin alpha v beta 3 is independent of the pathway that 
activates MMP-2. A disruption of this mechanism has been shown to inhibit 
angiogenesis and tumor growth, however, the details of the mechanism has not 
been elucidated.107,184   Another study suggests that the disruption of MMP-2 
binding to integrin alpha v beta 3 inhibits the invasion of mouse peritoneal 
macrophages.214 In addition to data concerning the outcome in the inhibition of 
MMP-2/integrin v beta 3 binding, a recent study demonstrated that the beta3 
antagonist m7E3 (abciximab) reduced the activity of MMP-2 and MMP-9 as well 
as smooth muscle cell migration in rats.10 
 A currently accepted model of integrin mediated cell migration is that a 
ligand or signaling induced by another agonist might bind to the cytoplasmic 
domain of the alpha-subunit and induce a conformational change by splitting the 
cytoplasmic domains of the alpha and beta subunits. In the inactive form, the 
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alpha-subunit inhibits the interaction between the beta-subunit and the 
cytoskeletal components. Consequently, this inhibition can be removed by ligand 
binding. The rate of binding between integrins and ligands is increased during 
integrin clustering. Intrinsically, the binding to ligands with multiple binding sites 
or by cytoskeletal interactions may lead to the clustering of integrins. 88,207 
Subsequently, the integrins associate with alpha-actinin, leading to a stable 
interaction with the cytoskeleton.171 
 As mentioned previously, integrins are in a constitutively active 
conformation in adherent cells. Our findings indicate that MMP-2, as a ligand of 
integrin alpha v beta 3, might influence macrophage behaviors indirectly through 
the expression of integrin beta3 or directly by interacting with integrin alpha v 
beta 3. Chapter 1 discussed the importance of many studies that demonstrated 
MMP-2 facilitated cell migration through a cleaving the ECM. However, there are 
controversial opinions about the role of MMP-2 in cell adhesion.57,167,217 This 
discrepancy may be due to the various ECM and cell types used, but most likely 
is linked to the limited understanding of the processes and mechanisms 
influencing adhesion turnover in migrating cells.  It was reported that MMP-2 
influences neutrophil-endothelial adhesion by cleaving the latent endothelin-1 
(ET-1) to the potent ET-1 in vitro.58,59 Mouse macrophages express MMP-2 in a 
relative small amount as compared to MMP-9 (Figure 3.5). However, in the 
present study, we demonstrated for the first time that MMP-2 deficiency reduced 
adhesion activity of mouse peritoneal macrophages. This reduction in adhesion 
might be due to a reduction in integrin beta 3 expression. 
 Future studies are required to determine the influence of MMP-2 on other 
adhesion molecules, such as selectins, VCAM, ICAM, and other integrins. Also, 
more experiments are required to determine the role of MMP-2 in the regulation 
of other cell behaviors such as survival and apoptosis as well. 
 Although the exact mechanism underlying the reduced integrin beta 3 
expression on MMP-2 deficient macrophages is unknown, several hypotheses 
may account for this observation. First, MMP-2 might upregulate integrin 
expression by influencing the activity of certain growth factors. As mentioned 
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previously (in Chapter 1), MMP-2 can modify the activity of many growth factors 
through multiple pathways. For example, MMP-2 facilitates the release of TGF-
beta by degrading the collagen-associated proteoglycan decorin, which is an 
anchor protein of TGF- beta. MMP-2 can proteolytically cleave and activate latent 
TGF-beta as well. Since TGF-beta is able to upregulate the expression of 
integrins,220 MMP-2 might upregulate integrin expression via increasing TGF-
beta activity. Moreover, MMP-2 may decrease the activity of basic fibroblast 
growth factor (bFGF) by cleaving the FGF receptor-1. There are controversial 
opinions for the role of bFGF in the expression of integrin alpha v beta 3 in 
microvascular endothelial cells. Klein et al. reported that bFGF decreased alpha 
v beta 3 expression. 109 On the contrary, Sepp et al. demonstrated that bFGF 
increased alpha v beta 3 integrin expression. 179 It is reported that recombinant 
VEGF is able to upregulate integrin alpha v beta 3 expression in human 
microvascular endothelial cells.178 However, there is not evidence that VEGF 
activity can be influenced by MMP-2. Taken together, the reduced integrin beta 3 
expression on MMP-2 deficiency macrophage might be due to the loss of local 
MMP-2 control on growth factors, especially, TGF-beta and bFGF. Another 
potential mechanism is based on the evidence that the expression of integrins 
can be controlled by the interactions between cells and their surrounding ECM.44 
The degradation of the ECM by MMP-2 might influence the integrin expression of 
cells. Other leukocytes, especially T lymphocytes, play important roles in 
vascular diseases. In this study, we did not determine the influence of MMP-2 on 
other types of inflammatory cells. Future studies are required to test these 
hypotheses. 
 We detected a tendency of enhanced production of MMP-9 in mouse 
peritoneal macrophages of MMP-2 deficient mice. This discovery is supported by 
recent evidence showing a 10-fold increase in the inactive form of MMP-9 in 
macrophages by gene transfection did not reduce the rupture of atherosclerotic 
plaques in carotid arteries of mice (Gough P. presented in the 6th annual 
conference on Atherosclerosis, Thrombosis and Vascular Biology, 2005). 
Although MMP-9 can be activated by several serine proteinases, it was reported 
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that proMMP-9 activation was accomplished by the active forms of MMP-2. 
These forms are generated after the activation of TIMP-2-free proMMP-2 on the 
surface of cancer cells. Regarding that study, we concluded that MMP-2 might be 
important in the regulation of macrophage behaviors by interacting with integrin 
alpha v beta 3. Therefore, MMP-2 is involved in cell adhesion and invasion 
through multiple pathways, not just its ability to digest the ECM. 
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Figure 4.1  Pathways outlining the influence of integrin alpha v beta 3 on 
cell behaviors. Integrins mediate cell adhesion to ECM and to other cells 
through activating a variety of protein tyrosine kinases like focal adhesion kinase 
(FAK) and Src-family kinases. Integrins also initiate intracellular signaling 
molecules that control cell shape, adhesion, migration, proliferation, 
differentiation and survival. In adherent cells, integrins are apparently in a 
constitutively active confirmation. Interaction between integrins and receptor 
kinases (RTKs) affects cell migration and surface expression levels of integrins. 
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Figure 4.2  The influence of MMP-2 and integrin alpha v beta 3 interaction 
on macrophage invasion  Numbers of macrophages invading through matrigel 
in the presence of no serum,10% FBS, or 10% FBS with TSRI265 (n = 4 wells 
per group). Histobars represent the means and bars are SEM. *P < 0.01 for 
comparisons of TSRI265 treated versus untreated MPMs; #P < 0.01 for 
comparisons of wells with FBS versus wells without FBS 
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Figure 4.3  Disruption of MMP-2 binding to integrin alpha v beta 3 did not 
influence macrophage adhesion. BCA protein assay for macrophages shows 
attachment to the plate after 3 hours incubation either with or without TSRI265 
10µM and washing (n = 6 wells per group) Histobars represent the means and 
bars are SEM. 
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Figure 4.4 Reduced adhesion activity of MMP-2 deficient macrophages     
(A) After 30 minutes culturing and washing, the macrophages attached in the 
plate were counted. (n = 5 wells per group) (B) BCA protein assay for the 
macrophages attached in the plate after 30 minutes incubation and washing (n = 
3-5 wells per group; *P < 0.001 for comparisons of MMP-2 wild type versus 
MMP-2 deficient macrophages) Histobars represent the means and bars are 
SEM. 
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Figure 4.5 RT-PCR of integrin beta 3 expression in MMP-2 deficient 
macrophages. RT-PCR was performed to semi-quantify the integrin beta3 
mRNA from macrophages of MMP-2 wild type and deficient mice. The expected 
amplicons for integrin beta3 were less pronounced in MMP-2 deficient 
macrophages compared with MMP-2 wild type macrophages. Beta actin mRNA 
signals were used as loading controls. 
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Figure 4.6 Immunofluorescence staining of integrin beta 3 expression in 
MMP-2 deficient macrophages.  Immunofluorescence staining for integrin beta 
3 on macrophages was performed. Staining was much less pronounced in 
macrophages of MMP-2 deficient mice (B) as compared with macrophages of 
MMP-2 wild type mice (A). Hoechst nuclear staining was performed in the same 
field of A (C) and B (D), respectively. 
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Figure 4.7 Flow cytometry of integrin beta 3 expression in MMP-2 deficient 
macrophages. The percentage of integrin beta 3 expression positive peritoneal 
macrophages was reduced in MMP-2-/- mice compared to wild type mice (n = 
4/group; P < 0.05). 
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Chapter Five 
 
The Effects of MMP-2 Deficiency in Bone Marrow-Derived 
Cells on AngII-Induced AAAs and Atherosclerosis 
in ApoE-/- Mice (in vivo) 
 
I. Background 
 
 There are two common features in the pathogenesis and evolution of 
abdominal aortic aneurysms (AAAs) and atherosclerosis: infiltration of 
inflammatory cells (especially macrophages and lymphocytes) into the vascular 
wall and remodeling of the extracellular matrix (ECM) at the site of 
inflammation.63,170 These two pathologic processes collaborate to form a vicious 
cycle in the progression of vascular diseases. Proteases and cytokines are 
enhanced by infiltrative macrophages, and this elaboration accelerates ECM 
degeneration; vice versa, the degradation of ECM components facilitates the 
infiltration of inflammatory cells into the vascular wall and leads to an elaboration 
of proteases and cytokines in situ.49,157 Therefore, proteases and cytokines might 
serve the primary linkage of this cycle. 
 As a protease, MMP-2 (gelatinase A) is involved in  cell-to-cell and cell-to-
matrix interactions in many physiological and pathological processes such as 
wound healing, cancer metastasis, and inflammatory joint diseases. MMP-2 first 
attracted attention in cardiovascular diseases primarily because of its ability to 
digest a diverse array of ECM components (including elastin and collagen) of the 
vascular wall. Furthermore, it was reported that MMP-2 facilitated neutrophil-
endothelial cell adhesion through cleaving pro-endothelin into an active form in 
vitro.58 Our previous study (in Chapter 4) demonstrated that macrophage-derived 
MMP-2 regulates macrophage adhesion and invasion through interacting with 
integrin alpha v beta 3. All of the above suggests that MMP-2 is not only involved 
in the remodeling of the ECM via the proteolysis of ECM components, but also 
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may be implicated in the infiltration of inflammatory cells into the vessel wall by 
modulating cell behaviors. 
 The bone marrow transplantation technique provided a useful approach to 
examine the contribution of hematopoietic cell gene expression to diseases. 
Bone marrow transplantation in the apoE-/- and LDLr-/- mouse models has been 
well established as a method for examining the effect of protein expression by 
inflammatory cells on the development of cardiovascular diseases. The 
repopulation of peripheral blood leukocytes by the transplanted bone marrow-
derived cells can be confirmed. 14,124 It was also reported that the lethally 
irradiated mice without bone marrow transplantation died within 14 days after the 
irradiation.162 
 In this study, we addressed the hypothesis that the MMP-2 produced by 
bone marrow-derived cells might play an important role in AngII-induced vascular 
diseases in vivo. MMP-2 gene targeted mice were used to achieve this purpose 
as bone marrow donors. 
 
II. Materials and Methods 
 
Animals 
 
 MMP-2-/- mice and apoE-/- mice were mated and bred. F1 (MMP-2+/- x 
apoE+/-) mice were mated to produce littermates of MMP-2+/+ x apoE-/- and 
MMP-2-/- x apoE-/- mice (F2).  Six- week-old male MMP-2+/+ and MMP-2-/- x 
apoE-/- littermates were used as bone marrow donors. These mice were 
genotyped by PCR as described previously (in Chapter 2). Six-week-old male 
apoE-/- mice were used as bone marrow-derived cell recipients. 
 
Experimental protocol 
 The experiment was designed as follows: 
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Bone marrow-derived cell transplantation 
 
 One week prior to irradiation and bone marrow transplantation, mice were 
given prophylactic treatment with the antibiotic sulfatrim (4 mg/ml) via their 
drinking water. ApoE-/- recipient mice were irradiated with 900 rads from a 
cesium γ source, given as a single dose.  Bone marrow was harvested from the 
femurs and tibias of MMP-2-/- and their littermate MMP-2+/+ x apoE-/- (n = 
4/group) mice by flushing with Hank’s buffered saline solution (1 ml).  Cells were 
washed, re-suspended, and counted. Irradiated recipient apoE-/- mice (n = 14-
17/group) were injected intravenously via the tail vein with 7 x 106 bone marrow 
cells from donor mice.  The mice were maintained on antibiotic water for four 
weeks following irradiation. After an interval of 6 weeks to permit hematopoietic 
engraftment, the study was initiated. 
 
All of the following experiments were performed as described in Chapter 2: 
PCR (polymerase chain reaction) for mouse genotyping 
AngII infusion and blood pressure measurement 
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Peripheral white blood cell counting 
Serum lipids and lipoprotein determination 
Quantification of atherosclerosis 
Classification of AAAs 
 
Statistics 
 Data are presented as means ± SEM. Two-way ANOVA (two factor 
analysis of variance) was performed to analyze experiments with two 
independent variables (i.e. AngII treatment and genotype of MMP-2).  One-way 
ANOVA was performed to test the equality of three or more means with one 
independent variable at one time by using variances. Student’s t-test was used to 
test the difference between two groups. All of the statistical analyses as above 
were done by a SigmaStat 2.03 software (SPSS Inc.). A repeating ANOVA was 
performed to analyze the data of the systolic blood pressure of the mice using a 
SAS software. Fisher exact probability test was used to determine differences 
between groups in the incidence of aneurysm formation.  Values with P < 0.05 
were considered statistically significant. 
 
III. Results 
 
Repopulation of irradiated apoE-/- mice with MMP-2+/+ or MMP-2-/- bone 
marrow-derived cells 
 
 Gelatin zymography of aortic extracts was performed to confirm genotypes 
of the donor mice. As predicted, the band of gelatin lysis by MMP-2 was not 
visualized in the extracts of aortas of MMP-2 deficient mice. The bone marrow of 
the recipient mice was harvested at the time of sacrifice and genotyped by PCR. 
The 1.1 kb amplified DNA product of mutant allele was detected only in bone 
marrow derived cell DNA from MMP-2-/- bone marrow recipient mice, but not in 
the DNA from MMP-2+/+ bone marrow transplanted control mice. This suggests 
that the transplanted bone marrow cells successfully repopulated the bone 
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marrow of recipient mice (Figure 5.1). 
 
Effect of bone marrow transplantation and AngII infusion on blood 
composition of the recipient mice 
 
 Blood was collected via retro-orbital bleeding and analyzed (n = 9 -11 
mice were chosen randomly for each group) one day before the termination of 
the experiment (Table 5.1). MMP-2 genotypes of the bone marrow-derived cells 
did not lead to a significant difference in the number of white blood cell (WBC), 
red blood cell (RBC), hemoglobin (Hb) or platelet.  AngII infusion did not change 
peripheral blood WBC and platelet count. Interestingly, AngII infusion caused a 
significant rise in the number of RBC and a corresponding increase in Hb level 
for both MMP-2 deficient and MMP-2 wild type bone marrow cell recipient mice  
(P < 0.001). 
 
Effect of bone marrow transplantation and AngII infusion on the body 
weight of the recipient mice 
 
 The recipient mice did not gain body weight as normal mice due to the 
irradiation (Figure 5.2; n = 14 -16/group). There was a significant loss of body 
weight in AngII infused mice compared with saline infused mice (-2.2 ± 0.3 g vs. 
1.3 ± 0.3 g; P < 0.001). However, there was no statistical difference between 
MMP-2+/+ and -/- bone marrow-derived cell recipient mice (P = 0.499). 
 
Effect of bone marrow transplantation and AngII infusion on the blood 
pressure of the recipient mice 
 
 Systolic blood pressure was measured in conscious mice using a 
computerized non-invasive tail-cuff system, 5 days per week (n = 10 -11/group). 
Saline infusion did not change systolic blood pressure of the recipient mice. AngII 
infusion increased systolic blood pressure in both MMP-2+/+ and -/- bone 
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marrow-derived cell recipient mice (P < 0.0001). There was a significant change 
of blood pressure caused by the interaction between AngII infusion and time 
within the AngII treated mice (P < 0.001; Figure 5.3). Neither MMP-2 genotype in 
bone marrow cells caused significant differences in blood pressure. 
 
Effect of bone marrow transplantation and AngII infusion on the cholesterol 
profile of the recipient mice 
 
 The genotype of MMP-2 of bone marrow-derived cells and AngII infusion 
did not cause statistically significant difference in total serum cholesterol 
concentrations (TC). For MMP-2+/+ bone marrow recipients, the TC was 183 ± 
12 mg/dl in saline group vs. 204 ± 20 mg/dl in AngII group; for MMP-2-/- bone 
marrow recipients, the TC was 161 ± 6 mg/dl in saline group vs. 190 ± 21 mg/dl 
in AngII group. There was a mild increase of TC in AngII infused mice (n = 9 -
10/group; P = 0.138; Figure 5.4). No significant difference was detected in 
lipoprotein distribution in MMP-2+/+ and MMP-2-/- bone marrow transplanted 
mice (Figure 5.5). 
 
Effect of bone marrow transplantation on AngII-induced hypertrophy of the 
aortic arch of the recipient mice 
 
 AngII infusion induced significant hypertrophy in the aortic arches of 
recipient mice. The aortic arch area was increased significantly in AngII-infused 
mice as compared to saline-infused mice (P < 0.001). However, MMP-2 
deficiency in bone marrow derived cells did not ablate the hypertrophy (Figure 
5.6; n = 10-11/group; P = 0.728). For saline infused mice, the area of aortic arch 
was 16.0 ± 0.7 mm2 in MMP-2+/+ bone marrow-derived cell recipients vs. 16.0 ± 
0.5 mm2 in MMP-2-/- bone marrow-derived cell recipients. For AngII treated mice, 
the area of aortic arch was 21.7 ± 0.8 mm2 in MMP-2+/+ bone marrow cell 
recipients vs. 21.2 ± 0.7 mm2 in MMP-2-/- bone marrow cell recipients. 
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The repopulation of MMP-2-/- bone marrow-derived cells significantly 
decreased the atherosclerosis formation in the recipient mice 
 
 The extent of atherosclerosis was quantified both by en face analysis of 
the aortic arch and thoracic aorta (Figure 5.7 and 5.8) and sequential cross 
sectioning of the aortic root (Figure 5.9). Both methods demonstrated a 
significant reduction of AngII-induced atherosclerosis in MMP-2-/- bone marrow 
cell-repopulated mice as compared to MMP-2+/+ bone marrow cell-repopulated 
mice (2.1 ± 0.2% vs. 5.7 ± 0.6% of thoracic aorta and aortic arch area, P < 0.001; 
7.2 ± 2.5 x 10-3 mm2 vs. 24.5 ± 6.7 x 10-3 mm2 of the lesion area on the 
transverse sections of aortic root, P < 0.05). Saline-infused MMP-2-/- bone 
marrow transplanted mice demonstrated a tendency toward reduction of 
atherosclerosis compared to wild type bone marrow recipient mice (0.2 ± 0.0% 
vs. 0.7 ± 0.2% of thoracic aorta and aortic arch area; 2.9 ± 1.0 x 10-3 mm2 vs. 8.2 
± 2.5 x 10-3 mm2 of plaque area on the transverse sections of aortic root). 
However, this was not statistically significant. 
 
The repopulation of MMP-2-/- bone marrow-derived cells prevented the 
AngII-induced AAA formation in the recipient mice 
 
 Abdominal aortic aneurysms were not detected in saline-infused recipient 
mice. AngII infusion (1,000 ng/kg/min) generated AAAs in 53% (nine out of 
seventeen) of mice with MMP-2+/+ bone marrow derived cells and 12.5% (two 
out of sixteen) of mice with MMP-2-/- bone marrow derived cells (n = 14 -
17/group; P < 0.05; Figure 5.11). There was no statistical difference between 
saline and AngII infused MMP-2-/- bone marrow derived cell recipients (P = 
0.30). AAAs were classified into four classes based on the standard that was 
described in Chapter 2. Both AAAs occurred in MMP-2-/- bone marrow cell 
recipient mice were type II AAAs. Among MMP-2+/+ bone marrow recipient mice, 
one type I, five type II, and one type III AAAs developed. In addition, two MMP-
2+/+ bone marrow-derived cell recipient mice died from AAA rupture, which is 
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defined as type IV AAAs, at the 8th and 10th day of AngII infusion, respectively 
(Figure 5.11). Abdominal aortas were weighed to provide an index of AAA 
severity. In saline-infused mice, MMP-2 deficiency in bone marrow-derived cells 
did not influence the weight of the abdominal aorta of mice.  However, abdominal 
aorta weight increased markedly after AngII infusion compared with saline 
infusion (P < 0.001). This increase was significantly attenuated in MMP-2-/- bone 
marrow-derived cell transplanted mice. The weight of abdominal aorta was 23.2 
± 2.1 mg in MMP-2+/+ bone marrow-derived cell recipients vs. 16.8 ± 1.2 mg in 
MMP-2-/- bone marrow-derived cell recipients (n = 14 -16/group, P < 0.05; Figure 
5.12). 
 
IV. Discussion 
 
In this study, our major finding is that MMP-2 deficiency in bone marrow-
derived cells decreased the incidence of AngII-induced AAA and the severity of 
atherosclerosis in apoE-/- mice. Linked with the reduced invasion ability of 
peritoneal macrophage of MMP-2 deficient mice, this result is rational. The 
immunohistochemical staining for macrophage indicated a reduction of 
macrophage content in atherosclerotic plaques of MMP-2-/- bone marrow cell 
recipient mice. However, this might be due to the reduced plaque size in these 
mice (Figure 5.10). Further study is required to quantify the reduction and 
evaluate the significance of the difference. 
 The apoE-/- mouse model is considered to be the most useful model for 
atherosclerosis analysis because of its high histological similarity to human 
diseases. In this model, macrophages are the major cellular component of the 
atherosclerotic plaque. At the age of 5 to 6-weeks, apoE-/- mice demonstrated 
monocytic adhesion and trans-endothelial migration to the endothelial surface of 
the aorta, detected by electron microscopy (EM). At 6 to 10-week-old, most 
apoE-/- mice have developed fatty-streak lesions comprised primarily of foam 
cells with a small number of migrating smooth muscle cells. These fatty-streak 
lesions rapidly progress to advanced lesions, which are typically comprised of a 
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necrotic core surrounded by proliferating smooth muscle cells and varying 
amounts of ECM, including collagen and elastin.145  In AngII-induced AAAs, the 
infiltration of macrophage into the vascular wall is a predominant feature also 
found in human disease. Taken together, a reasonable conclusion can be that 
reduced infiltration of macrophages might influence both atherosclerosis and 
AAAs development. 
 However, there was a discrepancy between the results of the current 
study and those of a previous study, which demonstrated that MMP-2 deficiency 
was not protective for atherosclerosis and AAAs in apoE-/- mice (in Chapter 2). 
Several potential mechanisms may explain the contradiction. First, the research 
community is realizing that results obtained through analysis of gene function in 
transgenic mice may differ from pharmacological interventions, which are 
relatively short-termed. The transgenic animal may develop effective adaptations 
to the long-term change regarding gene expression. For instance, deletion of an 
isoform of NOS (nitric oxide synthase) led to an up-regulation of other NOS 
isoforms in mice. In myoglobin null mice, an elevated capillary density was 
observed which enhances the oxygen supply to tissues.72 Discrepancies 
between results from clinical trials using a pharmacological blockade of integrins 
for cancer therapy and results from animal studies utilizing the genetic deletion of 
integrins provide an example of the contradiction in methods. This controversy 
has raised a discussion of the potential role of these integrins in angiogenesis 
and the safety and efficacy of integrin antagonists. 23 A bone marrow 
transplantation experiment is similar to a study utilizing short-term 
pharmacological treatment rather than the transgenic loss of gene function in the 
animal. 
 Second, irradiation itself may influence the development of vascular 
diseases. Ionizing irradiation is a risk factor for the development of 
atherosclerosis via inducing the release of inflammatory cytokines. Moreover, 
irradiation injures endothelial cells and increases vascular permeability. In the 
current study, recipient mice received high dose gamma-irradiation, which might 
influence the processes of atherosclerosis dramatically. It was reported that total 
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body gamma irradiation and syngeneic bone marrow (BM) reconstitution 
increased atherosclerosis area in the aortic root but decreased atherosclerosis 
area in thoracic aorta in LDLr-/- mice fed with high fat diet for 16 weeks. The 
reasons for this discrepancy remain unresolved.176 Unfortunately, there is not a 
counterpart study in apoE-/- mice. In this dissertation project, we observed that, 
after AngII-infusion, irradiated and syngeneic BM transplanted apoE-/- mice had 
a tendency to have larger atherosclerotic plaques in the aortic root when 
compared to non-irradiated mice (24.5 ± 6.7 x 10-3 mm2 vs. 10.0 ± 3.8 x 10-3 
mm2; P = 0.114). There was a significant difference in the percentage of 
atherosclerotic lesion to total surface area of aortic arch between irradiated and 
BM transplanted mice and non-irradiated mice (6.7 ± 0.4% vs. 3.1 ± 0.8%; P < 
0.001). These unpublished results affirm the effect of irradiation in human 
atherosclerosis. We do not have saline control in the non-irradiated mice 
because of limitations in the number of MMP-2 x apoE-/- mice available. 
 Irradiation might exacerbate inflammatory cell infiltration into the vessel 
wall during atherosclerosis development, thereby, intensifying the beneficial 
effect of impaired infiltration ability of MMP-2 deficient inflammatory cells. 
Flanders et al. reported that mice lacking Smad3, which is a critical downstream 
signaling molecule of TGF-beta, are protected against cutaneous injury induced 
by ionizing radiation. 61 TGF-beta is a potent chemotactic factor of monocytes, 
and induces macrophage to secret cytokines. 208 As mentioned before, TGF-beta 
can be activated by MMP-2. Although there is lack of an investigation in the role 
of TGF-beta in irradiation-induced atherosclerotic lesion, a reduced local TGF-
beta activation by MMP-2 deficient inflammatory cells might be protective. 
There is lack of evidence suggest that ionizing irradiation is a risk factor of 
AAAs. Some clinical studies suggest that beta-irradiation for the treatment of in-
stent restenosis does not increase the aneurysm incidence in patients .196 
However, there are several clinical trials which indicate that carotid artery 
aneurysms can be induced by radiotherapy for head and neck cancer. 
Histopathology findings of irradiation-induced aneurysm include carotid artery 
necrosis and an incomplete and fragmented endothelial lining. 152, 177 The 
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exacerbation of inflammatory cell infiltration into the vascular wall might 
contribute to irradiation-induced aneurysm formation as well. 
 The hematopoietic system contributes many cell types including 
circulating leukocytes, resident macrophages in tissues and organs. Bone 
marrow transplantation (BMT) technique using gene-targeted mice as donors 
and recipients provides a useful approach to examine the contribution of 
hematopoietic cell gene expression for diseases in vivo. 
 Some experiments suggest that resident progenitor cells in the adventitia 
are the source of smooth muscle cells in atherosclerotic lesions, and bone 
marrow progenitor cells hardly differentiate into resident cells in the vascular 
wall.87 However, other studies suggest that hematopoietic stem cells can 
differentiate into vascular cells, which take part in the pathogenesis of 
atherosclerosis.173 This controversy might be due to the limitation of techniques 
used to distinguish and determine the origin of stem cells in tissue and organs. 
Although there are controversial opinions, it should be noted that bone marrow-
derived cells are progenitors that have high plasticity. Therefore, a bone marrow 
transplantation experiment can be inherently flawed due to an inability to exclude 
the contribution of other types of cells, such as endothelial cells 215 and 
VSMCs.173 Taken together, although it could not change the central conclusions 
of this study as described above, irradiation and bone marrow transplantation 
might influence the development of vascular diseases. This might contribute to 
the apparent discrepancy between the findings of the current study and those of 
a previous study (in Chapter 2). 
 Hemodynamic conditions regulate vascular remodeling, monocyte 
adhesion and transmural migration in murine AAA models.181 Although AngII 
infusion dramatically increased mouse systolic blood pressure, MMP-2 deficiency 
in bone marrow-derived cells did not ablate AngII-induced hypertension. This 
indicates that the protective effect caused by the deletion of MMP-2 from bone 
marrow-derived cells was not due to the control of blood pressure. 
 Interestingly, AngII infusion caused a significant rise in the number of 
RBCs and a corresponding rise in the Hb levels in the blood of study mice. 
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Several clinical observations suggest that AngII is responsible for inappropriately 
sustaining production of erythropoietin despite hematocrit elevation, and is 
capable of directly stimulating the erythroid progenitors in bone marrow to 
produce erythrocytes.75,169 However, the mechanism is unclear. Another study 
released an opposing result, stating that under physiological conditions in healthy 
volunteers, increased concentrations of endogenous AngII is not a major factor of 
erythropoietin regulation. 64 In addition, MMPs/TIMPs are secreted by normal 
human bone marrow hematopoietic cells and stromal cells and may play an 
important role in intercellular cross-talk during hematopoiesis.132 To fully 
understand the dramatic effects we have observed in the current study, the role 
of MMP-2 in the regulation of behavior of stem cells should be considered. 
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Table 5.1 Blood cell compositions of bone marrow-derived cell recipient mice 
 
MMP-2 genotype 
of BM MMP-2 +/+ MMP-2-/- 
Infusion Saline AngII Saline AngII 
WBC 
(1x103 cells/mm3) 10.1 ± 0.7 7.9 ± 0.9 8.1± 0.6 7.5 ± 1.1 
RBC 
(1x 106 cells/mm3) 9.3 ± 0.2 11.5 ± 0.3* 9.6 ± 0.1 11.0 ± 0.8* 
Platelets 
(1x103 cells/mm3) 992 ± 36 918 ± 61 1052 ± 40 976 ± 81 
Hb (g/dl) 14.3 ± 0.3 16.7± 0.3* 14.5 ± 0.2 17.0 ± 0.5* 
 
Data represent mean ± SEM for groups of 9-11 mice. 
*P<0.001 with respect to saline infused mice of the same MMP-2 genotype 
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Figure 5.1 Confirmation of MMP-2 genotype of bone marrow donors and 
recipient mice (A) Gelatin zymography of extracts (15µg) of aortas of MMP-2+/+ 
and -/- x apoE-/- mice. No MMP-2 expression was detected in MMP-2 deficient 
mice, whereas a prominent 72kDa band of gelatin lysis by MMP-2 was present in 
the MMP-2 wild type mice. (B) Representative PCR genotyping of bone marrow 
removed from recipient mice transplanted with either MMP-2+/+ or -/- bone 
marrow-derived cells. The 1.1 kbp (for the mutant allele) band was detected in 
the DNA of bone marrow from MMP-2-/- bone marrow recipient mice and was 
absent in bone marrow of the control transplanted mice. 
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Figure 5.2 Effect of bone marrow-derived cell transplantation and AngII 
infusion on the body weight of recipient mice.  There was no effect of MMP-2 
genotype in bone marrow-derived cells on the body weight of the study mice. 
However, AngII infusion caused a significant loss of body weight compared with 
saline infusion (*P < 0.001).  Points represent the means of 14 -16 mice and bars 
are SEM. 
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Figure 5.3  Effect of bone marrow-derived cell transplantation and AngII 
infusion on the blood pressure of recipient mice. Mini-pumps filled with saline 
or AngII (1,000 ng/kg/min) were implanted subcutaneously into the mice at day 0 
(n = 10-11/group). Saline infusion did not change systolic blood pressure of the 
recipient mice. There was a significant change in blood pressure during AngII 
infusion in the treated mice. A repeating ANOVA was used to analyze this data 
(#P < 0.0001 for comparisons of AngII versus saline infusion within MMP-2 
genotypes;  †P < 0.001 for analysis of the interaction between AngII infusion and 
time within AngII treated mice). Points represent the means of measurements of 
each week and bars are SEM. 
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Figure 5.4 Effect of bone marrow-derived cell transplantation and AngII 
infusion on the total cholesterol plasma concentration of recipient mice.  
Serum total cholesterol concentrations were measured using commercially 
available enzymatic assay kits. There was no significant difference in serum 
cholesterol concentrations across groups (n = 9-10/group). Histobars represent 
the means and bars are SEM. BM stands for bone marrow. 
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Figure 5.5 Effect of bone marrow-derived cell transplantation and AngII- 
infusion on the lipoprotein distribution of recipient mice. Lipoprotein 
distribution of mice was resolved using size exclusion chromatography, namely, 
fast performed lipid chromatography (FPLC). The curves of VLDL, LDL/IDL and 
HDL of the mice were overlapped. Points represent the means of 9-10 individual 
mice, and bars are SEM. S is saline-infused mice; A is AngII-infused mice. 
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Figure 5.6 Effect of bone marrow-derived cell transplantation on AngII-
induced hypertrophy on the aortic arch of recipient mice. AngII infusion 
caused a significant increase in the intima area of the aortic arch of the recipient 
mice. There was no difference between MMP-2+/+ and -/- bone marrow-derived 
cell recipient mice. Values obtained from individual mice are represented as open 
symbols, the means are represented as closed symbols and SEM as bars. (n = 
10-11/group; # P < 0.001 for comparisons of AngII versus saline infusion within 
MMP-2 genotypes) BM stands for bone marrow. 
 
 
 
 
 
 
 
 
 
 
 104
 
 
 
 
Figure 5.7 Representative light photomicrographs of luminal surface of 
aortic arch and thoracic aortas of the recipient mice. The aortas were stained 
with Oil Red O. Red-stained areas are atherosclerotic lesions. AngII-infusion (E 
and G) accelerates atherosclerosis development in mice as compared to saline 
infusion (A and C). MMP-2-/- bone marrow cell recipient mice (C and G) have 
reduced atherosclerotic lesion as compared to MMP-2+/+ bone marrow cell 
recipient mice (A and E). B, D, F, and H show the detail of boxed area in A, C, E, 
and G, respectively. 
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Figure 5.8 Effect of bone marrow-derived cell transplantation on AngII-
induced atherosclerosis on the intima of the aortic arch and thoracic aorta 
of recipient mice. The percentage of the intimal area covered by atherosclerotic 
lesion was quantified in the aortic arch and thoracic aorta. Infusion of AngII 
increased the area of atherosclerosis in both MMP-2 +/+ and -/- bone marrow-
derived cell recipient mice. There was a significant reduction in AngII-induced 
atherosclerosis in MMP-2-/- BM-derived cells recipient mice compared to MMP-
2+/+ BM-derived cells recipient mice (n = 10-11/group; ** P < 0.001 for 
comparisons of MMP-2 -/- versus MMP-2+/+ within AngII infused groups; † P < 
0.001 for comparisons of AngII versus saline infusion within MMP-2+/+ mice; †† 
P < 0.01 for comparisons of AngII versus saline infusion within MMP-2 -/- mice. 
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Figure 5.9  Effect of bone marrow-derived cell transplantation on AngII-
induced atherosclerosis in aortic roots of recipient mice Reduced severity of 
atherosclerosis was observed in the sections of aortic root in mice with MMP-2-/- 
bone marrow-derived cells. Values obtained from individual mice are represented 
as open symbols, the means are depicted as closed symbols and SEM as bars. 
(n = 8/group; *P < 0.01 for comparisons of MMP2+/+ versus -/- within AngII or 
saline infused groups; †P < 0.01 for comparisons of AngII versus saline infusion 
within MMP-2+/+ mice) 
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Figure 5.10 Effect of bone marrow-derived cell transplantation on 
macrophage infiltration in AngII-induced atherosclerosis in aortic roots 
from recipient mice Representative photomicrographs of immunohistochemical 
staining for macrophage on cross-cryosections of aortic roots were shown. 
Staining was less pronounced in MMP-2-/- bone marrow cell recipient mice (B) 
as compared to MMP-2+/+ bone marrow recipient mice (A). This indicates a 
reduced macrophage infiltration in the atherosclerotic lesions in MMP-2-/- bone 
marrow cell recipient mice. However, it might be due to a reduced size of 
atherosclerosis in these mice. Bars indicate 50 µm. C and D show the detail of 
boxed area in A and B, respectively. 
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Figure 5.11 Effect of bone marrow-derived cell transplantation on the 
incidence of AngII-induced AAAs in recipient mice  The absence of MMP-2 in 
bone marrow-derived cells decreased the incidence of AngII-induced AAA in 
apoE -/- mice compared with MMP-2 wild type bone marrow transplanted mice. 
(n = 14-17 per group; *P < 0.05) BM is for bone marrow. 
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Figure 5.12  Effect of bone marrow-derived cell transplantation on the 
severity of AngII-induced AAAs in recipient mice   Abdominal aortas were 
isolated by cutting the aorta at the level of the diaphragm and the iliac bifurcation.  
The tissue was weighed to provide an index of AAA severity. Values obtained 
from individual mice are represented in open symbols, the means are shown as 
closed symbols and SEM as bars (n = 14-16 per group). These data do not 
include the tissue weight of two mice (both were MMP-2+/+ bone marrow cell 
recipient mice) that died from AAA rupture during AngII infusion. * P < 0.05 for 
comparisons of MMP2+/+ versus -/- within AngII infused mice; #P < 0.01 for 
comparisons of AngII versus saline infusion within mice with same MMP-2 
genotypes 
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Chapter Six 
 
General Discussion and Future Studies 
 
 Atherosclerosis and AAAs are distinguishable, vascular diseases that 
have some common features. For example, they share certain risk factors such 
as smoking, aging, and male gender. Furthermore, population-based studies 
demonstrate that a considerable number of patients with AAAs have a history of 
atherosclerosis. Two prominent pathological characteristics of both 
atherosclerosis and AAAs are the infiltration of inflammatory cells (especially 
macrophages and lymphocytes) into the vascular wall and the remodeling of the 
extracellular matrix (ECM) at the site of inflammation.63,170 Proteases, especially 
MMPs, and cytokines play key roles in these pathological processes. 
 There is evidence that MMP-2 is involved in atherosclerosis and AAA 
formation. Primarily, the secretion and activation of MMP-2 is elevated in both 
atherosclerosis and AAA lesions.43,74 Also, abluminal application of CaCl2-
induced AAA formation was ablated in MMP-2 knock out mice.126 MMP-2 
deficiency led to reduced intimal hyperplasia in mouse carotid artery blood flow 
cessation model as well.101,114 The understanding of the mechanism behind 
these results is still superficial, although some hypothesize that MMP-2 functions 
in ECM remodeling and facilitating cell migration by destroying the barrier around 
the cell.  
 The primary purpose of the current dissertation project was to evaluate the 
general hypothesis that MMP-2 plays an important role in hyperlipidemia and 
AngII-induced atherosclerosis and AAAs. We also sought to determine if there is 
a greater role of MMP-2 beyond just the cleavage of elastin. By using apoE-/- 
double knockout mice in this project, we were able to evaluate the role of MMP-2 
deficiency in hyperlipidemia as well as atherosclerosis. Four studies were 
completed to test the overall hypothesis. 
 First, we investigated the development of atherosclerosis and AngII-
induced AAAs in MMP-2-/- and MMP+/+ mice on an apoE-/- background. It was 
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surprising that MMP-2 deficiency did not reduce the incidence of AngII-induced 
AAAs or the size of atherosclerotic lesions in apoE-/- mice. However, the cellular 
and ECM content of atherosclerotic plaques was modified in MMP-2-/- x apoE-/- 
when compared to MMP-2+/+ x apoE-/- control mice. To explain the apparent 
paradox between this result and the hypothesis, we investigated the 
morphological characteristics of the aortic wall of MMP-2-/- mice in a 
hyperlipidemic background. We detected an enhanced MMP-9 level in the aortic 
wall of MMP-2-/- x apoE-/- mice compared with MMP-2+/+ x apoE-/- mice. 
Interestingly, we also observed more branches in the elastin fibers of the aortic 
wall from MMP-2-/- mice when compared with aortic walls of wild type mice. 
Next, we examined the behavior of macrophages of MMP-2-/- mice. Reduced 
adhesion, migration and expression of integrin beta 3 were detected in the 
macrophages of MMP-2 deficient mice when compared with the macrophages of 
wild type control mice. Lastly, to examine whether MMP-2 deficiency in bone 
marrow-derived cells could influence AAAs and atherosclerosis, we implemented 
a phase of bone marrow transplantation. There was a significant reduction of 
both atherosclerosis development and AAAs formation in mice receiving 
reconstituted MMP-2-/- bone marrow cells. 
 The most encouraging finding in this dissertation project is that bone 
marrow cell-derived MMP-2 is critical in AngII-induced AAAs and atherosclerosis 
in apoE-/- mice. In spite of enhancing MMP-9 expression (mainly in an inactive 
form), the peritoneal macrophages of MMP-2-/- mice have an impaired adhesion 
and invasion ability, which might be due to a reduced integrin beta 3 expression. 
Consistent with this finding, it was reported that a 10-fold increase in the inactive 
form of MMP-9 in macrophages by gene transfection did not reduce the 
atherosclerotic lesion in apoE deficient mice (Data presented by P. Gough at the 
6th annual conference on Atherosclerosis, Thrombosis and Vascular Biology, 
2005). Although MMP-9 can be activated by several serine proteinases, the 
active form of MMP-2, generated after the activation of TIMP-2-free proMMP-2 
on the cell surface, might activate proMMP-9. Based on our findings, we 
concluded that MMP-2 deficiency in bone marrow-derived cells reduced AngII-
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induced AAAs and atherosclerosis, and this reduction might be due to reduced 
adhesion and migration ability of macrophages. According to the shortcomings of 
MMP inhibitors, such as toxicity and lack of specificity, these findings could lead 
to new targeted-molecular approaches to the prevention and treatment of 
atherosclerosis and AAAs. 
 At first, it seems that there is a contradiction between the dramatic 
protective effect from MMP-2 deficiency in bone marrow-derived cells and the 
data we obtained from the study of MMP-2-/- x apoE-/- mice, in which MMP-2 
deficiency did not reduce the incidence of AAAs or the size of atherosclerosis. 
However, this discrepancy might provide an insight into the importance of the 
interaction among various cell types and MMPs in the development of vascular 
diseases. There are two hypotheses which may account for this discrepancy: 1) 
MMP-2 produced by resident cells of the vessel wall (especially SMCs) is 
supplemental in atherogenesis and AAA formation and 2) the overexpression of 
MMP-9 in SMCs is critical for atherosclerosis and AAA formation in apoE-/- mice, 
but the overexpression of MMP-9 in macrophages is not. 
 Although inflammatory cells play a pivotal role in the initiation and 
progression of both diseases, the participation of other cell types, especially 
VSMCs and endothelial cells, is critical as well. In AAAs, VSMCs play a key role 
in the remodeling of aortic wall. VSMCs synthesize matrix proteins, such as 
collagen, elastin, and proteoglycans. They also secrete proteolytic enzymes, 
including MMPs, that digest the matrix proteins and turnover the ECM of the 
aortic wall. In rats, implantation of VSMCs prevented AAA formation in an aortic 
xenograft model.4 Proliferation and migration of VSMCs in the subendothelial 
space is a prominent pathological feature of atherosclerotic lesions. Multiple 
MMPs (including MMP-2 and 9) are involved in the migration of VSMCs. 
Although MMP-2 and MMP-9 have a redundancy in their substrate profile, it is 
possible that they bind to a diverse range of receptors and elicit different patterns 
of cell behaviors in various types of cell. On the basis of our study, we concluded 
that integrin alpha v beta 3 might serve as a receptor for MMP-2 on the 
macrophage membrane. This conclusion is supported by our data suggesting 
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that TSRI265 reduced the invasion ability of MPMs. Enhanced MMP-9 
expression did not reconstitute this adhesion ability in MMP-2 deficient 
macrophages. Although MMP-9 is produced in relatively small amounts by 
VSMCs when compared to MMP-2, it appears to regulate smooth muscle cell 
adhesion and migration through its interaction with CD44, a hyaluronan 
receptor.101 Taken together, these data highly suggested that MMPs bind to 
various receptors and influence cell behaviors through autocrine and/or paracrine 
pathways. However, more studies must be done to elucidate mechanisms 
underlying the interaction and regulation of these enzymes and their receptors to 
verify these hypotheses. In MMP-2-/- x apoE-/- mice, the increased MMP-9 
expression in the endothelium and/or VSMCs might overwhelm the beneficial 
effect from MMP-2 deficiency in macrophages. 
 MMP-2 might influence the proliferation and apoptosis of VSMCs as well. 
First, the proliferation of VSMCs is elicited by multiple growth factors, such as 
TGF-beta, IGF, and bFGF, through autocrine and/or paracrine pathways.12 
Although the mechanisms underlying these pathways are not fully understood, it 
is reasonable to hypothesize that MMP-2 might be involved in the VSMCs 
proliferation through modifying the activity of growth factors. Second, MMPs 
might process and release the Fas ligand (FasL), which is an integral membrane 
protein homologous with TNF and mediates apoptosis of Fas+ target cells, in a 
soluble form (sFasL). Treatment with inhibitors of MMPs led to a reduction of 
sFasL and an accumulation of membrane-type Fas ligand (mFasL).102,105,198 
sFasL, lacking transmembrane and cytoplasmic domains, is a poor mediator of 
apoptosis, whereas full-length mFasL is pro-apoptotic. sFasL derived from 
monocytes/macrophages and endothelial cells induces VSMCs apoptosis.18 This 
apoptotic effect from deregulation of growth factors and/or ablation of FasL 
processing might contribute to the diminished protection from AngII-induced 
AAAs in MMP-2 deficient, hyperlipidemic mice. More studies need to be done to 
test these hypotheses in future. 
 As mentioned in Chapter Three, two potential mechanisms might underlie 
the enhancement of MMP-9 expression in the aortic wall of MMP-2-/- x apoE-/- 
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mice. First, there might be compensatory overproduction MMP-9 in mice with 
MMP-2 gene deficiency. Second, it was reported that the MT1-MMP/TIMP-
2/MMP-2 complex, in addition to facilitating activation of pro-MMP-2, could be 
involved in regulating the expression of MMP-9.53 This indicates that MMP-2 
might be a critical component in the regulation of MMP-9 expression. 
 Both ECM remodeling and inflammatory cell recruitment are important for 
the maintenance of normal vascular physiological functions, such as healing 
post-injury. As a constitutively expressed enzyme, MMP-2 is involved in both 
processes. However, under pathological conditions, these processes might 
become overactive and shift to being harmful rather than protective for blood 
vessels, facilitating the development of atherosclerosis and AAAs. Therefore, a 
temporal or spatial regulation of MMP-2 instead of a simple deletion of the MMP-
2 gene might emerge as a desired prophylaxis and treatment of vascular 
diseases. To reach this goal, a full understanding of the redundant ECM 
proteolytic mechanisms (i.e. why are so many proteolytic enzymes involved in 
the remodeling of vascular wall?) in the development of vascular diseases is also 
critical. This requires the further understanding of the physiopathological specific 
situation, the cooperation of diverse types of cells, and the stimuli which induce 
synthesis and/or activation of individual MMPs in vascular diseases as well. 
 Through careful research and evaluation, the importance of MMP-2 in 
cardiovascular diseases has been realized in the last decade. Traditionally, 
MMP-2 was thought to release cells from the ECM simply by its elastiolytic 
capability. However, the role of MMP-2 in ECM degradation may be more 
complex. Combined with the realization of the critical role of ECM in regulating 
signaling molecules for cell behaviors, other insights were taken into the 
evaluation of the potential role of ECM-digestive enzymes in both physiological 
and pathological processes. Our major findings in the current dissertation support 
that the role of MMP-2, which is an important extracellular protease and 
constitutively expressed in vascular wall, goes far beyond that of remodeling the 
ECM only. MMP-2 can be involved in the regulation of cell behaviors as well. 
This new perspective may lead to exciting new approaches in the intervention of 
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cardiovascular diseases. It could be pivotal in understanding the subtle 
interaction involved in cell-to-matrix and cell-to-cell interaction.  However, future 
studies will have to determine the pathways required by these enzymes for the 
activation and regulation of various cell types under diverse physiopathological 
conditions. These studies might contribute to a further understanding of the role 
of MMP-2 in vascular diseases. 
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ABBREVIATIONS 
 
AA   amino acid 
AAA   abdominal aortic aneurysm 
ACE    angiotensin-converting enzyme  
AngII   angiotensin II 
apoE   apolipoprotein E 
BM   bone marrow 
BP   blood pressure 
CD   cluster differentiation 
CHD   coronary heart disease 
ECM   extracellular matrix 
EGF   epidermal growth factor  
EPC   endothelial progenitor cell 
ET   endothelin 
FACS fluorescence activated cell sorting/flow 
cytometry 
FGF   fibroblast growth factor 
Hb   hemoglobin 
HDL   high density lipoprotein 
ICAM     intercellular adhesion molecule 
IGF   insulin-like growth factor  
IGFBP   insulin-like growth factor binding protein 
LDL   low density lipoprotein 
IL   interleukin  
LRP   low density lipoprotein-related protein 
MCP-1   macrophage chemoattractant protein-1 
MMP   matrix metalloproteinase 
MPM   mouse peritoneal macrophage 
MT-MMP   membrane type-MMP 
O.C.T.    optimal cutting temperature 
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Opn   osteopontin 
ox-LDL   oxidized LDL 
PAI-1   plasminogen activator inhibitor-1 
PCAM   platelet endothelial cellular adhesion molecule 
PCR   polymerase chain reaction 
PDGF   platelet-derived growth factor 
PG   prostaglandin  
RAAS   renin-angiotensin-aldosterone system 
RAP   receptor-associated protein 
RBC   red blood cell 
ROS   reactive oxygen species 
RT   room temperature 
RT-PCR reverse transcription polymerase chain 
reaction 
TC   total cholesterol 
TGF   transforming growth factor 
TIMP   tissue inhibitor of matrix metalloproteinase 
tPA   tissue plasminogen activator 
uPA   urokinase-type plasminogen activator 
VCAM     vascular cell adhesion molecule  
VEGF   vascular endothelial growth factor 
VSMC   vascular smooth cell 
WBC   white blood cell 
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